C137_contig_2475_10	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.7	115	516	204	9.36e-08	51.6
C137_contig_2475_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	22.6	106	516	228	3.18e-06	47.4
C137_contig_2475_28	CARD|gb|ATC67679.1|ARO:3000838|arlR	23.3	129	497	219	1.15e-06	48.5
C137_contig_5106_9	SARG|DQ212986.1.gene3.p01	55.6	63	68	75	4.01e-20	74.7
C137_contig_5106_24	SARG|YP_001373621	53.2	218	252	318	3.92e-76	232
C137_contig_5106_24	SARG|gi|447057510|ref|WP_001134766.1|	53.7	218	252	309	5.98e-76	231
C137_contig_5106_24	SARG|gi|445996732|ref|WP_000074587.1|	53.7	218	252	309	1.20e-75	231
C137_contig_5106_24	SARG|gi|445996723|ref|WP_000074578.1|	49.6	240	252	309	1.20e-75	231
C137_contig_5106_24	SARG|gi|445996719|ref|WP_000074574.1|	53.2	218	252	309	1.69e-75	230
C137_contig_5106_24	SARG|gi|445996729|ref|WP_000074584.1|	53.2	218	252	309	1.69e-75	230
C137_contig_5106_24	SARG|gi|445996722|ref|WP_000074577.1|	49.2	240	252	309	1.69e-75	230
C137_contig_5106_24	SARG|gi|895808656|emb|COR83787.1|	53.2	218	252	309	1.69e-75	230
C137_contig_5106_24	SARG|gi|1043490477|ref|WP_065382463.1|	49.2	240	252	309	3.40e-75	229
C137_contig_5106_24	SARG|gi|445996726|ref|WP_000074581.1|	49.2	240	252	309	3.40e-75	229
C137_contig_5106_25	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	42.3	227	235	229	3.53e-54	172
C137_contig_5106_25	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.4	227	235	232	7.00e-52	167
C137_contig_5106_25	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.4	227	235	232	7.00e-52	167
C137_contig_5106_25	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.7	220	235	228	1.12e-49	161
C137_contig_5106_25	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.9	227	235	231	1.38e-48	158
C137_contig_5106_25	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.4	231	235	233	2.06e-48	158
C137_contig_5106_25	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.1	231	235	232	4.50e-47	154
C137_contig_5106_25	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.2	231	235	232	1.27e-46	153
C137_contig_5106_25	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.5	224	235	230	1.70e-46	153
C137_contig_5106_25	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.0	229	235	231	1.74e-46	153
C137_contig_5106_26	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.8	325	462	368	1.33e-20	92.0
C137_contig_5106_26	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.1	284	462	367	8.60e-19	86.7
C137_contig_5106_26	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	21.9	306	462	392	1.17e-16	80.5
C137_contig_5106_26	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	23.4	286	462	380	1.44e-16	80.1
C137_contig_5106_26	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	23.4	286	462	380	1.44e-16	80.1
C137_contig_5106_26	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.1	290	462	381	2.68e-15	76.3
C137_contig_5106_26	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	21.8	293	462	381	2.68e-15	76.3
C137_contig_5106_26	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.1	290	462	381	2.68e-15	76.3
C137_contig_5106_26	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	21.8	293	462	381	2.68e-15	76.3
C137_contig_5106_26	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.9	292	462	381	6.41e-15	75.1
C137_contig_5106_34	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.7	111	532	228	5.04e-12	64.7
C137_contig_5106_34	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.3	120	532	219	1.63e-10	60.1
C137_contig_5106_34	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.3	113	532	204	6.54e-09	55.1
C137_contig_5106_44	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.4	121	693	229	7.07e-15	73.6
C137_contig_5106_44	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.6	117	693	230	3.26e-14	71.6
C137_contig_5106_44	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.7	129	693	231	2.25e-12	66.2
C137_contig_5106_44	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.0	124	693	231	3.04e-12	65.9
C137_contig_5106_44	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.0	119	693	239	1.14e-11	64.3
C137_contig_5106_44	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.1	121	693	247	1.27e-11	64.3
C137_contig_5106_44	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.2	124	693	231	1.36e-11	63.9
C137_contig_5106_44	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.0	114	693	232	1.38e-11	63.9
C137_contig_5106_44	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.0	114	693	232	1.38e-11	63.9
C137_contig_5106_44	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.2	124	693	231	1.84e-11	63.5
C137_contig_5106_54	SARG|gi|923061916|ref|WP_053445667.1|	42.7	213	235	648	1.39e-47	165
C137_contig_5106_54	SARG|gi|895865878|ref|WP_048974758.1|	40.8	213	235	646	1.84e-46	162
C137_contig_5106_54	SARG|gi|495736522|ref|WP_008461101.1|	38.1	236	235	648	3.59e-46	161
C137_contig_5106_54	SARG|gi|746243059|ref|WP_039291473.1|	37.7	236	235	648	3.59e-46	161
C137_contig_5106_54	SARG|gi|746253210|ref|WP_039301529.1|	38.1	236	235	648	3.59e-46	161
C137_contig_5106_54	SARG|gi|1001720867|ref|WP_061274204.1|	37.7	236	235	648	9.51e-46	160
C137_contig_5106_54	SARG|gi|694064328|ref|WP_032410816.1|	39.9	213	235	646	4.72e-45	158
C137_contig_5106_54	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.3	224	235	575	3.80e-19	84.7
C137_contig_5106_54	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.2	216	235	664	1.35e-18	83.2
C137_contig_5106_54	SARG|gi|739906046|ref|WP_037756452.1|	27.2	224	235	620	2.43e-18	82.4
C137_contig_5106_57	SARG|Q83LR7	36.8	266	255	648	5.72e-42	150
C137_contig_5106_57	SARG|gi|647325472|ref|WP_025760953.1|	36.8	266	255	648	5.72e-42	150
C137_contig_5106_57	SARG|gi|647323678|ref|WP_025760497.1|	36.8	266	255	648	5.72e-42	150
C137_contig_5106_57	SARG|gi|446110305|ref|WP_000188160.1|	36.5	266	255	648	2.06e-41	149
C137_contig_5106_57	SARG|gi|1001720867|ref|WP_061274204.1|	37.2	234	255	648	7.40e-41	147
C137_contig_5106_57	SARG|gi|495736522|ref|WP_008461101.1|	37.2	234	255	648	1.02e-40	147
C137_contig_5106_57	SARG|gi|545254099|ref|WP_021550525.1|	37.0	265	255	648	1.40e-40	146
C137_contig_5106_57	SARG|gi|746253210|ref|WP_039301529.1|	37.2	234	255	648	1.40e-40	146
C137_contig_5106_57	SARG|gi|693057297|ref|WP_032225054.1|	37.0	265	255	648	1.40e-40	146
C137_contig_5106_57	SARG|gi|446110277|ref|WP_000188132.1|	37.0	265	255	648	1.40e-40	146
C137_contig_3495_6	SARG|ABB80128	29.3	225	252	306	2.05e-32	119
C137_contig_3495_6	SARG|P42332	28.9	225	252	306	2.15e-31	116
C137_contig_3495_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.9	225	252	306	2.15e-31	116
C137_contig_3495_6	SARG|gi|510143239|gb|AGN36970.1|	28.9	225	252	313	2.46e-31	116
C137_contig_3495_6	SARG|AAD21213	28.4	225	252	306	1.60e-30	114
C137_contig_3495_6	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	194	252	655	5.22e-11	61.2
C137_contig_3495_6	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	194	252	655	5.22e-11	61.2
C137_contig_3495_6	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	210	252	655	5.22e-11	61.2
C137_contig_3495_6	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	194	252	655	5.22e-11	61.2
C137_contig_3495_6	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	194	252	655	5.22e-11	61.2
C137_contig_3495_18	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	26.8	228	300	346	3.32e-17	79.7
C137_contig_3495_20	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	25.7	272	334	346	4.62e-12	65.1
C137_contig_3495_24	SARG|gi|1035735809|ref|WP_064572349.1|	31.8	406	396	648	2.76e-45	164
C137_contig_3495_24	SARG|gi|446110351|ref|WP_000188206.1|	32.1	399	396	648	5.22e-45	163
C137_contig_3495_24	SARG|gb|AAV85982.1|ARO:3000535|macB	31.0	397	396	644	6.91e-45	163
C137_contig_3495_24	SARG|gi|487410704|ref|WP_001678420.1|	31.8	406	396	648	9.88e-45	162
C137_contig_3495_24	SARG|gi|545164255|ref|WP_021518974.1|	31.6	408	396	648	2.57e-44	161
C137_contig_3495_24	SARG|gi|693170426|ref|WP_032302787.1|	31.8	406	396	648	2.57e-44	161
C137_contig_3495_24	SARG|gi|742907943|ref|WP_039020462.1|	31.8	406	396	648	2.57e-44	161
C137_contig_3495_24	SARG|gi|446110310|ref|WP_000188165.1|	31.8	406	396	648	2.57e-44	161
C137_contig_3495_24	SARG|gi|693106883|ref|WP_032260279.1|	31.8	406	396	648	3.54e-44	161
C137_contig_3495_24	SARG|gi|485866062|ref|WP_001464282.1|	31.5	406	396	648	3.54e-44	161
C137_contig_3495_25	SARG|gi|772669624|ref|WP_045284511.1|	23.5	187	367	371	4.98e-07	50.1
C137_contig_3495_25	SARG|gi|980965841|ref|WP_059386160.1|	23.5	187	367	371	4.98e-07	50.1
C137_contig_3495_25	SARG|gi|647318711|ref|WP_025756035.1|	23.5	187	367	371	4.98e-07	50.1
C137_contig_3495_25	SARG|gi|847053738|ref|WP_047958145.1|	23.5	187	367	371	4.98e-07	50.1
C137_contig_3495_25	SARG|gi|770791620|ref|WP_045134670.1|	23.5	187	367	371	6.62e-07	49.7
C137_contig_3495_25	SARG|gi|695722594|ref|WP_032649222.1|	23.5	187	367	371	6.62e-07	49.7
C137_contig_3495_25	SARG|gi|1022678038|ref|WP_063433938.1|	23.5	187	367	371	6.62e-07	49.7
C137_contig_3495_25	SARG|gi|835759367|ref|WP_047653122.1|	23.7	186	367	371	6.62e-07	49.7
C137_contig_3495_25	SARG|gi|504696094|ref|WP_014883196.1|	23.5	187	367	371	6.62e-07	49.7
C137_contig_3495_25	SARG|gi|640459949|ref|WP_024907815.1|	23.5	187	367	371	8.80e-07	49.3
C137_contig_3495_35	SARG|gb|AJP77059|ARO:3003670|PEDO-1	31.7	145	215	286	1.74e-16	75.1
C137_contig_3495_35	SARG|EU408354.1.gene5.p01	31.9	144	215	294	1.89e-16	75.1
C137_contig_3495_35	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	33.8	142	215	342	2.52e-15	72.4
C137_contig_3495_35	NCBI|WP_073552023.1|1|1|blaGOB-47|blaGOB|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_GOB-47|AMR|beta-lactam	32.6	144	215	290	4.07e-14	68.6
C137_contig_3495_35	SARG|gb|WP_019050927.1|ARO:3005671|GOB-22	32.6	144	215	290	4.07e-14	68.6
C137_contig_3495_35	SARG|gb|WP_069213816.1|ARO:3005676|GOB-27	32.6	144	215	290	4.07e-14	68.6
C137_contig_3495_35	SARG|gb|ACZ72746.1|ARO:3004808|GOB-16	32.6	144	215	290	4.07e-14	68.6
C137_contig_3495_35	SARG|gb|WP_041884311.1|ARO:3006972|PLN-1	31.5	143	215	289	5.53e-14	68.2
C137_contig_3495_35	SARG|gb|WP_078769980.1|ARO:3005695|GOB-46	31.3	144	215	290	5.57e-14	68.2
C137_contig_3495_35	SARG|gb|WP_078793281.1|ARO:3005693|GOB-44	31.9	144	215	290	7.64e-14	67.8
C137_contig_3495_67	SARG|DQ018711.1.gene4.p01	31.9	229	322	322	8.33e-30	114
C137_contig_3495_67	SARG|FJ349556.1.gene5.p01	33.5	197	322	326	4.62e-29	112
C137_contig_3495_67	SARG|gi|737310392|ref|WP_035293250.1|	31.4	229	322	323	1.17e-28	111
C137_contig_3495_67	SARG|gi|985522333|ref|WP_060811962.1|	28.0	275	322	323	3.12e-28	110
C137_contig_3495_67	SARG|gi|738848198|ref|WP_036737307.1|	32.3	229	322	323	4.33e-28	110
C137_contig_3495_67	SARG|gi|498515089|ref|WP_010815296.1|	28.0	275	322	323	8.32e-28	109
C137_contig_3495_67	SARG|gb|AAB05626.1|ARO:3002943|vanHB	28.4	275	322	323	1.60e-27	108
C137_contig_3495_67	SARG|Q47748	28.0	275	322	323	2.21e-27	108
C137_contig_3495_67	SARG|YP_002333394	28.0	275	322	323	8.14e-27	106
C137_contig_3495_67	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	27.6	275	322	323	1.56e-26	105
C137_contig_3495_68	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	31.6	282	320	351	2.59e-32	122
C137_contig_3495_68	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	31.3	281	320	343	4.34e-32	121
C137_contig_3495_68	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	31.4	280	320	348	9.16e-32	120
C137_contig_3495_68	SARG|gi|749574782|ref|WP_040203616.1|	27.8	284	320	323	1.57e-29	114
C137_contig_3495_68	SARG|KF478993.1.gene2.p01	31.0	277	320	350	1.80e-29	114
C137_contig_3495_68	SARG|CAB61228	29.1	282	320	322	4.12e-29	112
C137_contig_3495_68	SARG|NP_878015	27.1	277	320	322	7.95e-29	112
C137_contig_3495_68	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	28.3	297	320	323	1.12e-28	111
C137_contig_3495_68	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	31.3	252	320	237	1.99e-28	108
C137_contig_3495_68	SARG|YP_002333394	28.3	297	320	323	2.16e-28	110
C137_contig_3495_69	SARG|AAN28721	42.9	98	597	108	9.01e-18	78.2
C137_contig_3495_76	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.6	387	1282	1197	1.92e-50	194
C137_contig_3495_76	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	23.5	277	1282	341	2.12e-08	56.6
C137_contig_4618_34	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	48.8	213	214	223	1.63e-71	216
C137_contig_4618_34	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.2	227	214	235	2.35e-31	113
C137_contig_4618_34	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.6	181	214	231	3.01e-31	113
C137_contig_4618_34	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	31.8	198	214	239	7.18e-31	112
C137_contig_4618_34	CARD|gb|AAD51348.1|ARO:3003066|smeR	27.8	209	214	229	1.22e-29	108
C137_contig_4618_34	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.8	181	214	231	4.98e-29	107
C137_contig_4618_34	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	30.4	181	214	230	1.35e-28	106
C137_contig_4618_34	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.1	183	214	233	2.85e-28	105
C137_contig_4618_34	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	27.9	179	214	231	4.11e-27	102
C137_contig_4618_34	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	27.9	179	214	231	8.09e-27	101
C137_contig_4618_35	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	44.0	218	330	341	5.87e-55	181
C137_contig_4618_35	CARD|gb|AEX49906.1|ARO:3003583|basS	29.9	214	330	477	6.44e-18	83.2
C137_contig_4618_36	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	52.0	252	255	255	4.67e-89	263
C137_contig_4618_36	SARG|gi|495736522|ref|WP_008461101.1|	37.3	260	255	648	5.54e-55	186
C137_contig_4618_36	SARG|gi|545248218|ref|WP_021546584.1|	41.9	222	255	648	7.70e-55	185
C137_contig_4618_36	SARG|gi|746253210|ref|WP_039301529.1|	36.9	260	255	648	2.07e-54	184
C137_contig_4618_36	SARG|gi|1001720867|ref|WP_061274204.1|	36.9	260	255	648	2.07e-54	184
C137_contig_4618_36	SARG|gi|746243059|ref|WP_039291473.1|	37.3	260	255	648	5.57e-54	183
C137_contig_4618_36	SARG|gi|740856590|ref|WP_038641842.1|	41.6	221	255	648	5.57e-54	183
C137_contig_4618_36	SARG|gi|507086196|ref|WP_016156937.1|	41.6	221	255	648	5.57e-54	183
C137_contig_4618_36	SARG|YP_001571041	39.3	234	255	648	5.57e-54	183
C137_contig_4618_36	SARG|gi|922960663|ref|WP_053388845.1|	41.6	221	255	648	5.57e-54	183
C137_contig_4618_37	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	31.7	309	579	641	7.62e-33	132
C137_contig_1895_107	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	45.2	228	233	225	3.64e-63	195
C137_contig_1895_107	CARD|gb|AAC73788.1|ARO:3003841|kdpE	45.2	228	233	225	3.64e-63	195
C137_contig_1895_107	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.8	226	233	228	9.48e-45	148
C137_contig_1895_107	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.6	224	233	229	3.88e-44	147
C137_contig_1895_107	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.9	224	233	219	5.84e-44	146
C137_contig_1895_107	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.2	228	233	232	1.32e-42	143
C137_contig_1895_107	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.2	228	233	232	1.32e-42	143
C137_contig_1895_107	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.0	228	233	231	4.03e-41	139
C137_contig_1895_107	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.2	229	233	235	4.98e-40	136
C137_contig_1895_107	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.5	224	233	231	3.52e-39	134
C137_contig_1895_108	CARD|gb|CYF42523.1|ARO:3004047|kdpD	31.1	871	899	885	9.34e-145	450
C137_contig_1895_108	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.7	223	899	361	1.23e-15	78.6
C137_contig_1895_124	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.0	230	234	232	2.64e-54	173
C137_contig_1895_124	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.0	230	234	232	2.64e-54	173
C137_contig_1895_124	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.2	232	234	231	1.48e-50	163
C137_contig_1895_124	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.3	231	234	231	2.10e-50	163
C137_contig_1895_124	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.6	230	234	232	1.22e-49	161
C137_contig_1895_124	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.4	237	234	233	2.51e-49	160
C137_contig_1895_124	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.3	231	234	231	3.35e-49	160
C137_contig_1895_124	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.3	231	234	231	3.35e-49	160
C137_contig_1895_124	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	231	234	231	4.73e-49	159
C137_contig_1895_124	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	231	234	231	9.45e-49	159
C137_contig_1895_138	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.4	830	932	1024	1.51e-120	390
C137_contig_1895_138	SARG|gb|CAA53189|ARO:3000521|mupA	30.4	830	932	1024	1.51e-120	390
C137_contig_1895_138	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	30.4	830	932	1024	2.11e-120	390
C137_contig_1895_138	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.4	830	932	1024	2.11e-120	390
C137_contig_5609_31	ResF|penA_1_AF515059_1	24.0	578	747	581	1.70e-36	144
C137_contig_5609_31	SARG|gb|AQX82857.1|ARO:3004185|mecD	21.0	586	747	678	1.03e-12	70.5
C137_contig_5609_35	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	30.5	436	418	444	9.67e-55	186
C137_contig_5609_40	SARG|gb|AAC75314.1|ARO:3003578|pmrF	31.2	314	320	322	2.41e-38	137
C137_contig_1614_25	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	23.0	379	651	1107	8.33e-11	64.3
C137_contig_1614_25	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	23.0	379	651	1107	8.33e-11	64.3
C137_contig_1614_25	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.2	323	651	1024	1.85e-10	63.2
C137_contig_1614_25	SARG|gb|CAA53189|ARO:3000521|mupA	23.2	323	651	1024	1.85e-10	63.2
C137_contig_1614_25	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.2	323	651	1024	4.21e-10	62.0
C137_contig_1614_25	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.2	323	651	1024	4.21e-10	62.0
C137_contig_1614_25	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	24.1	266	651	1033	1.26e-09	60.5
C137_contig_1614_25	SARG|gb|AEY83581|ARO:3000510|mupB	24.1	266	651	1033	1.26e-09	60.5
C137_contig_6620_2	SARG|ABV82118	25.3	454	603	639	3.28e-26	112
C137_contig_6620_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	455	603	629	1.33e-25	110
C137_contig_6620_2	ResF|tet(O/W)_3_AM889120_1	26.2	455	603	639	1.37e-25	110
C137_contig_6620_2	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.8	435	603	639	1.82e-25	110
C137_contig_6620_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	455	603	629	2.35e-25	109
C137_contig_6620_2	SARG|gi|1004359922|gb|AMP42228.1|	26.6	455	603	639	2.43e-25	109
C137_contig_6620_2	SARG|AJ295238.gene.p01	24.8	435	603	639	2.43e-25	109
C137_contig_6620_2	SARG|ZP_03989103	24.6	435	603	639	2.43e-25	109
C137_contig_6620_2	SARG|ABV82120	24.6	435	603	639	2.43e-25	109
C137_contig_6620_2	ResF|tet(O/W)_4_AM889121_1	26.2	455	603	639	2.43e-25	109
C137_contig_6620_9	SARG|gi|974588181|ref|WP_059178476.1|	31.2	199	242	646	2.14e-18	82.8
C137_contig_6620_9	SARG|YP_001176128	31.2	199	242	646	2.14e-18	82.8
C137_contig_6620_9	SARG|gi|936194420|ref|WP_054528571.1|	30.0	200	242	648	3.92e-18	82.0
C137_contig_6620_9	SARG|gi|507086196|ref|WP_016156937.1|	30.5	200	242	648	3.92e-18	82.0
C137_contig_6620_9	SARG|gi|695701476|ref|WP_032638992.1|	28.6	227	242	646	5.30e-18	81.6
C137_contig_6620_9	SARG|gi|851928815|ref|WP_048221086.1|	30.0	200	242	648	9.73e-18	80.9
C137_contig_6620_9	SARG|gi|780033092|ref|WP_045444768.1|	30.0	200	242	648	9.73e-18	80.9
C137_contig_6620_9	SARG|gi|895872463|ref|WP_048979698.1|	30.2	199	242	646	1.32e-17	80.5
C137_contig_6620_9	SARG|gi|757799695|ref|WP_043016897.1|	30.0	200	242	648	1.32e-17	80.5
C137_contig_6620_9	SARG|gi|1045891604|ref|WP_065554100.1|	30.0	200	242	648	1.32e-17	80.5
C137_contig_6620_43	SARG|gi|500448961|gb|EOP61695.1|	27.9	229	233	306	1.53e-21	89.7
C137_contig_6620_43	SARG|gi|445996710|ref|WP_000074565.1|	27.3	231	233	309	3.05e-21	89.0
C137_contig_6620_43	SARG|gi|500465078|gb|EOP76697.1|	27.9	229	233	306	4.06e-21	88.6
C137_contig_6620_43	SARG|gi|445996719|ref|WP_000074574.1|	27.7	231	233	309	4.23e-21	88.6
C137_contig_6620_43	SARG|gi|895736250|emb|COF64653.1|	27.3	231	233	309	8.09e-21	87.8
C137_contig_6620_43	SARG|gi|446110087|ref|WP_000187942.1|	27.3	231	233	309	8.09e-21	87.8
C137_contig_6620_43	SARG|gi|445996722|ref|WP_000074577.1|	28.1	231	233	309	8.09e-21	87.8
C137_contig_6620_43	SARG|gi|895808656|emb|COR83787.1|	27.3	231	233	309	8.09e-21	87.8
C137_contig_6620_43	SARG|gi|445996714|ref|WP_000074569.1|	27.3	231	233	309	1.12e-20	87.4
C137_contig_6620_43	SARG|gi|445996723|ref|WP_000074578.1|	27.7	231	233	309	1.12e-20	87.4
C137_contig_6620_134	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	41.3	523	508	533	9.93e-110	335
C137_contig_6620_134	SARG|AF353562.gene.p01	41.3	366	508	369	1.04e-65	216
C137_contig_6620_146	SARG|gb|AAG04750.1|ARO:3004077|PmpM	23.9	401	455	477	1.21e-19	90.1
C137_contig_6620_146	SARG|YP_001445425	21.6	398	455	456	8.65e-18	84.3
C137_contig_6620_146	NCBI|AAG27731.1|1|1|norM-Burk|norM-Burk|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_NorM|AMR|efflux	26.1	410	455	462	1.57e-14	74.3
C137_contig_6620_146	SARG|BAA31456	19.0	395	455	456	3.57e-13	70.1
C137_contig_6620_146	SARG|YP_302230	24.3	230	455	451	4.55e-06	47.8
C137_contig_6620_242	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.3	195	351	255	3.72e-25	101
C137_contig_6620_242	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.7	212	351	258	8.60e-21	89.4
C137_contig_6620_242	SARG|gb|AAK76137.1|ARO:3000024|patA	25.9	205	351	564	1.54e-10	61.2
C137_contig_6620_242	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	23.4	201	351	579	1.09e-07	52.4
C137_contig_6620_242	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.8	157	351	362	1.89e-07	51.2
C137_contig_6620_242	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	23.4	201	351	579	1.92e-07	51.6
C137_contig_6620_242	SARG|gi|736993687|ref|WP_034989673.1|	63.6	33	351	513	5.41e-06	47.0
C137_contig_6620_242	SARG|AF024666.2.gene6.p01	63.6	33	351	513	5.41e-06	47.0
C137_contig_6620_242	SARG|gi|171851258|emb|CAQ04234.1|	63.6	33	351	483	9.25e-06	46.2
C137_contig_4221_1	SARG|gi|738272573|ref|WP_036227195.1|	59.8	97	106	492	1.65e-37	130
C137_contig_4221_1	SARG|gi|640690880|ref|WP_025115215.1|	58.8	97	106	492	2.30e-37	130
C137_contig_4221_1	SARG|gi|924348018|ref|WP_053483923.1|	59.8	97	106	492	4.44e-37	129
C137_contig_4221_1	SARG|gi|738205817|ref|WP_036161732.1|	57.0	100	106	492	6.17e-37	129
C137_contig_4221_1	SARG|gi|1032346815|ref|WP_064200323.1|	62.5	96	106	492	6.17e-37	129
C137_contig_4221_1	SARG|gi|950274036|ref|WP_057309929.1|	61.5	96	106	492	8.58e-37	128
C137_contig_4221_1	SARG|gi|902795376|ref|WP_049664555.1|	58.8	97	106	492	8.58e-37	128
C137_contig_4221_1	SARG|gi|926256269|ref|WP_053594535.1|	58.8	97	106	492	1.19e-36	128
C137_contig_4221_1	SARG|gi|1031496106|ref|WP_064100483.1|	61.5	96	106	492	1.19e-36	128
C137_contig_4221_1	SARG|gi|951389844|ref|WP_057765492.1|	60.4	96	106	492	2.30e-36	127
C137_contig_4221_2	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	50.8	197	222	494	9.21e-53	176
C137_contig_4221_2	SARG|gi|844766676|ref|WP_047933873.1|	44.9	198	222	492	1.05e-49	167
C137_contig_4221_2	SARG|gi|817727729|ref|WP_046680744.1|	44.9	198	222	492	2.87e-49	166
C137_contig_4221_2	SARG|gb|AEA37904.1|ARO:3003112|lsaC	49.4	176	222	492	4.01e-49	166
C137_contig_4221_2	SARG|gi|763097172|ref|WP_043977684.1|	44.9	198	222	492	5.61e-49	166
C137_contig_4221_2	SARG|gi|902795376|ref|WP_049664555.1|	46.0	198	222	492	1.10e-48	165
C137_contig_4221_2	SARG|gi|550167391|ref|WP_022586684.1|	44.9	198	222	492	1.53e-48	164
C137_contig_4221_2	SARG|gi|924348018|ref|WP_053483923.1|	45.5	198	222	492	2.15e-48	164
C137_contig_4221_2	SARG|gi|445983949|ref|WP_000061804.1|	48.1	181	222	492	2.15e-48	164
C137_contig_4221_2	SARG|gi|489438834|ref|WP_003344330.1|	44.9	198	222	492	2.15e-48	164
C137_contig_4221_10	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	4.36e-117	362
C137_contig_4221_10	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	8.64e-117	362
C137_contig_4221_10	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.22e-116	361
C137_contig_4221_10	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.22e-116	361
C137_contig_4221_10	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.22e-116	361
C137_contig_4221_10	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.22e-116	361
C137_contig_4221_10	SARG|gb|AKA86814|ARO:3003746|optrA	34.4	627	638	655	1.22e-116	361
C137_contig_4221_10	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.71e-116	361
C137_contig_4221_10	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.71e-116	361
C137_contig_4221_10	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	627	638	655	1.71e-116	361
C137_contig_4221_38	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	33.2	434	428	444	3.40e-54	185
C137_contig_4221_40	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	46.5	159	160	159	1.26e-42	138
C137_contig_4221_49	SARG|gb|AAV85982.1|ARO:3000535|macB	35.8	386	387	644	2.13e-55	191
C137_contig_4221_49	SARG|gi|446110286|ref|WP_000188141.1|	33.6	390	387	648	3.91e-44	160
C137_contig_4221_49	SARG|gi|1015927937|ref|WP_062886781.1|	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|gi|446110290|ref|WP_000188145.1|	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|gi|446110330|ref|WP_000188185.1|	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|gi|654658955|ref|WP_028119847.1|	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|gi|921979807|ref|WP_053271336.1|	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|YP_002328441	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|gi|952011484|ref|WP_057915969.1|	33.6	390	387	648	7.40e-44	160
C137_contig_4221_49	SARG|gi|426326769|emb|CCK10228.1|	33.6	390	387	648	1.02e-43	159
C137_contig_4221_50	SARG|gi|639225329|ref|WP_024561799.1|	50.0	218	226	648	2.11e-65	212
C137_contig_4221_50	SARG|gi|639218559|ref|WP_024556062.1|	50.0	218	226	648	2.11e-65	212
C137_contig_4221_50	SARG|gi|657888313|ref|WP_029592374.1|	50.0	218	226	648	2.95e-65	212
C137_contig_4221_50	SARG|gi|671541568|ref|WP_031525212.1|	50.0	218	226	648	2.95e-65	212
C137_contig_4221_50	SARG|gi|498115003|ref|WP_010429159.1|	49.1	228	226	646	5.58e-65	211
C137_contig_4221_50	SARG|gi|835330218|ref|WP_047457825.1|	49.5	218	226	648	5.77e-65	211
C137_contig_4221_50	SARG|YP_001453760	49.5	218	226	648	5.77e-65	211
C137_contig_4221_50	SARG|YP_001176128	49.5	218	226	646	1.09e-64	210
C137_contig_4221_50	SARG|gi|696368937|ref|WP_032943949.1|	48.6	218	226	648	1.58e-64	210
C137_contig_4221_50	SARG|gi|446048048|ref|WP_000125903.1|	48.6	218	226	648	1.58e-64	210
C137_contig_4221_52	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.6	217	227	219	8.56e-45	148
C137_contig_4221_52	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	223	227	219	2.69e-40	136
C137_contig_4221_52	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	223	227	219	3.79e-40	136
C137_contig_4221_52	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	223	227	220	3.90e-40	136
C137_contig_4221_52	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	223	227	220	3.90e-40	136
C137_contig_4221_52	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	223	227	220	1.09e-39	135
C137_contig_4221_52	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.2	229	227	232	7.31e-37	128
C137_contig_4221_52	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.2	229	227	232	7.31e-37	128
C137_contig_4221_52	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.4	220	227	228	1.31e-36	127
C137_contig_4221_52	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.0	224	227	232	5.35e-33	118
C137_contig_4221_53	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.0	230	408	381	4.54e-22	95.9
C137_contig_4221_53	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.0	230	408	381	4.54e-22	95.9
C137_contig_4221_53	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.3	230	408	381	1.45e-19	88.6
C137_contig_4221_53	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.3	230	408	381	1.45e-19	88.6
C137_contig_4221_53	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	230	408	381	2.65e-19	87.8
C137_contig_4221_53	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	230	408	381	2.65e-19	87.8
C137_contig_4221_53	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.6	220	408	380	3.55e-19	87.4
C137_contig_4221_53	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.6	220	408	380	3.55e-19	87.4
C137_contig_4221_53	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	230	408	381	6.52e-19	86.7
C137_contig_4221_53	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	230	408	381	6.52e-19	86.7
C137_contig_4221_87	SARG|AAD42183	29.9	224	336	322	7.12e-21	90.5
C137_contig_4221_87	SARG|AAD51059	30.2	225	336	323	1.66e-19	86.7
C137_contig_4221_87	SARG|AAR37059	30.2	225	336	323	2.27e-19	86.3
C137_contig_4221_87	SARG|AAD41881	30.2	225	336	323	2.27e-19	86.3
C137_contig_4221_87	SARG|NP_878015	26.8	257	336	322	3.06e-19	85.9
C137_contig_4221_87	SARG|gi|749574782|ref|WP_040203616.1|	30.3	238	336	323	4.22e-19	85.5
C137_contig_4221_87	SARG|gi|740152780|ref|WP_037997109.1|	29.3	239	336	322	1.06e-18	84.3
C137_contig_4221_87	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	30.1	226	336	314	2.46e-18	83.2
C137_contig_4221_87	SARG|AY082011.1.gene6.p01	35.5	152	336	323	3.71e-18	82.8
C137_contig_4221_87	SARG|AAY52004	27.4	263	336	322	5.00e-18	82.4
C137_contig_4221_106	SARG|gi|487135741|ref|WP_001627648.1|	23.8	445	457	451	5.37e-31	123
C137_contig_4221_106	SARG|gi|446573715|ref|WP_000651061.1|	23.3	438	457	451	7.33e-31	122
C137_contig_4221_106	SARG|gi|1006223553|ref|WP_061745579.1|	23.5	438	457	451	7.33e-31	122
C137_contig_4221_106	SARG|ZP_03986195	23.8	445	457	451	1.00e-30	122
C137_contig_4221_106	SARG|gi|686408548|ref|WP_031913080.1|	23.8	445	457	451	1.37e-30	122
C137_contig_4221_106	SARG|gi|686432388|ref|WP_031921070.1|	23.8	445	457	451	1.37e-30	122
C137_contig_4221_106	SARG|gi|686448604|ref|WP_031928572.1|	23.6	445	457	451	1.37e-30	122
C137_contig_4221_106	SARG|gi|763462741|ref|WP_044292157.1|	23.1	438	457	451	2.55e-30	121
C137_contig_4221_106	SARG|gi|686294396|ref|WP_031862836.1|	23.1	438	457	451	2.55e-30	121
C137_contig_4221_106	SARG|gi|446573693|ref|WP_000651039.1|	23.6	445	457	451	2.55e-30	121
C137_contig_4221_157	SARG|JQ861959.1.gene5.p01	41.9	265	282	287	2.42e-67	210
C137_contig_4221_157	NCBI|WP_001255866.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	42.0	274	282	302	5.33e-67	209
C137_contig_4221_157	NCBI|WP_032491779.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	41.6	274	282	302	6.78e-65	204
C137_contig_4221_157	NCBI|WP_001255864.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	39.6	275	282	302	7.63e-64	201
C137_contig_4221_157	megares|MEG_992|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6_1	37.6	282	282	284	8.08e-62	196
C137_contig_4221_157	NCBI|WP_001255868.1|1|1|aadE|aadE|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_6-adenylyltransferase_AadE|AMR|aminoglycoside	38.0	276	282	288	1.44e-60	192
C137_contig_4221_157	SARG|FN594949.1.gene25.p01	37.7	276	282	285	1.87e-60	192
C137_contig_4221_157	SARG|P12055	33.7	279	282	282	5.67e-49	162
C137_contig_4221_157	SARG|CAA63519	33.3	279	282	282	8.00e-49	162
C137_contig_4221_157	SARG|AAT34976	33.3	279	282	282	2.24e-48	161
C137_contig_4221_165	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.8	258	383	355	1.20e-19	88.2
C137_contig_4221_165	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.8	258	383	355	1.20e-19	88.2
C137_contig_4221_165	SARG|ACM47285	29.8	258	383	363	1.30e-19	88.2
C137_contig_4221_165	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.5	258	383	356	2.24e-19	87.4
C137_contig_4221_165	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.1	258	383	356	1.39e-18	85.1
C137_contig_4221_181	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.4	261	380	355	2.10e-27	110
C137_contig_4221_181	SARG|BAE96115	31.4	261	380	355	2.10e-27	110
C137_contig_4221_181	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.3	235	380	355	2.89e-27	109
C137_contig_4221_181	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.3	235	380	355	2.89e-27	109
C137_contig_4221_181	SARG|ACM47285	32.3	235	380	363	3.25e-27	109
C137_contig_4221_181	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	31.3	198	380	209	5.94e-20	86.3
C137_contig_2509_5	SARG|YP_424819	79.9	149	150	261	1.81e-81	239
C137_contig_2509_5	SARG|BAE98117	79.9	149	150	264	2.00e-81	239
C137_contig_2509_5	SARG|CAA67773	79.9	149	150	264	2.00e-81	239
C137_contig_2509_5	SARG|AAK62562	79.9	149	150	264	2.00e-81	239
C137_contig_2509_5	SARG|CAD36021	79.2	149	150	264	1.15e-80	238
C137_contig_2509_5	SARG|P0A3Y6	78.5	149	150	263	1.48e-78	232
C137_contig_2509_5	NCBI|WP_004206941.1|1|1|aphA16|aphA16|phosphotransferase|2|AMIKACIN/KANAMYCIN|aminoglycoside|APH(3')_family_aminoglycoside_O-phosphotransferase_AphA16|AMR|aminoglycoside	34.7	150	150	262	8.35e-27	100
C137_contig_2509_5	SARG|gb|CAF29483.1|ARO:3002653|APH(3')-VIb	28.9	135	150	259	3.10e-13	63.9
C137_contig_2509_5	SARG|0910185A	32.0	97	150	262	8.47e-09	51.6
C137_contig_2509_5	SARG|P00553	32.0	97	150	262	1.16e-08	51.2
C137_contig_2509_6	NCBI|WP_000627290.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	99.1	111	113	180	1.64e-75	220
C137_contig_2509_6	NCBI|WP_063854935.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	92.8	111	113	180	2.34e-75	219
C137_contig_2509_6	megares|MEG_6166|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	98.2	111	113	180	6.69e-75	218
C137_contig_2509_6	megares|MEG_6165|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	91.9	111	113	180	9.50e-75	218
C137_contig_2509_6	SARG|gb|AAB53445.1|ARO:3002897|SAT-4	98.2	111	113	180	2.72e-74	217
C137_contig_2509_6	megares|MEG_6169|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	97.3	111	113	180	1.11e-73	215
C137_contig_2509_6	NCBI|WP_003242546.1|1|1|satA_Bsub|satA_Bsub|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_SatA|AMR|nucleoside	44.1	111	113	173	3.63e-32	110
C137_contig_2509_6	SARG|gb|AAP26981.1|ARO:3005045|SatA	30.0	110	113	184	4.67e-10	53.1
C137_contig_2509_7	SARG|AM410044.gene9.p01	99.0	103	296	112	1.09e-71	215
C137_contig_2509_7	SARG|AY712687.1.gene1.p01	99.0	103	296	276	2.16e-69	215
C137_contig_2509_7	SARG|NC_006663.1.orf0.gene.p01	99.0	103	296	279	2.37e-69	215
C137_contig_2509_7	NCBI|WP_032491779.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	99.0	103	296	302	4.74e-69	215
C137_contig_2509_7	NCBI|WP_001255866.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	99.0	103	296	302	4.74e-69	215
C137_contig_2509_7	NCBI|WP_001255864.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	99.0	103	296	302	4.74e-69	215
C137_contig_2509_7	SARG|AJ489618.1.orf2.gene.p01	87.4	103	296	237	6.21e-62	195
C137_contig_2509_7	SARG|gi|994929255|emb|CZA27509.1|	75.0	80	296	218	5.87e-38	132
C137_contig_2509_7	SARG|gi|486458841|gb|EOE03251.1|	75.0	80	296	237	9.72e-38	132
C137_contig_2509_7	SARG|JQ861959.1.gene5.p01	75.0	80	296	287	3.34e-37	132
C137_contig_2509_15	SARG|DQ212986.1.gene3.p01	44.4	63	77	75	1.27e-16	66.2
C137_contig_2509_71	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	29.4	690	663	703	4.84e-85	280
C137_contig_2509_77	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	55.9	492	493	494	6.19e-199	561
C137_contig_2509_77	SARG|gi|924348018|ref|WP_053483923.1|	53.7	492	493	492	3.62e-190	538
C137_contig_2509_77	SARG|gi|902795376|ref|WP_049664555.1|	53.9	492	493	492	7.28e-190	538
C137_contig_2509_77	SARG|gi|445983920|ref|WP_000061775.1|	53.5	492	493	492	4.17e-189	536
C137_contig_2509_77	SARG|gi|817727729|ref|WP_046680744.1|	53.0	492	493	492	4.17e-189	536
C137_contig_2509_77	SARG|gi|763097172|ref|WP_043977684.1|	52.8	492	493	492	1.69e-188	534
C137_contig_2509_77	SARG|gi|445983921|ref|WP_000061776.1|	53.3	492	493	492	1.69e-188	534
C137_contig_2509_77	SARG|gi|926256269|ref|WP_053594535.1|	53.3	492	493	492	4.81e-188	533
C137_contig_2509_77	SARG|gi|1005577494|ref|WP_061669299.1|	53.0	492	493	492	6.82e-188	533
C137_contig_2509_77	SARG|gi|1032346815|ref|WP_064200323.1|	53.7	492	493	492	6.82e-188	533
C137_contig_4053_40	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	60.4	53	59	416	2.04e-19	78.2
C137_contig_4053_79	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	27.8	133	291	301	7.77e-08	51.6
C137_contig_4053_84	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.0	223	502	255	4.89e-18	82.8
C137_contig_4053_84	SARG|gb|ABX00624.1|ARO:3002881|lmrC	26.1	501	502	550	2.02e-16	80.9
C137_contig_4053_84	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	29.9	184	502	343	9.95e-16	77.4
C137_contig_4053_84	SARG|gb|AAV85982.1|ARO:3000535|macB	28.5	221	502	644	3.00e-15	77.4
C137_contig_4053_84	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	26.1	387	502	568	4.48e-14	73.6
C137_contig_4053_84	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	26.3	395	502	487	2.73e-13	70.9
C137_contig_4053_84	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	24.9	482	502	487	3.63e-13	70.5
C137_contig_4053_84	SARG|gb|CBL58195.1|ARO:3002831|vgaC	26.5	392	502	522	3.92e-13	70.5
C137_contig_4053_84	NCBI|AFC62715.1|1|1|eat(A)|eat(A)|target_protection|0|PLEUROMUTILIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Eat(A)|AMR|pleuromutilin	31.9	182	502	500	1.53e-12	68.6
C137_contig_4053_84	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	25.8	384	502	461	3.26e-12	67.4
C137_contig_4053_90	SARG|gb|WP_104671188.1|ARO:3003948|efrA	48.6	502	718	575	9.50e-147	439
C137_contig_4053_90	SARG|gb|AAK76137.1|ARO:3000024|patA	36.3	512	718	564	9.44e-108	338
C137_contig_4053_90	SARG|gi|930482089|ref|WP_054228897.1|	35.5	361	718	599	7.71e-61	214
C137_contig_4053_90	SARG|gi|985844137|ref|WP_060895163.1|	35.5	361	718	599	7.71e-61	214
C137_contig_4053_90	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	30.5	495	718	579	6.90e-60	211
C137_contig_4053_90	SARG|gi|655401130|ref|WP_028800283.1|	34.7	360	718	599	5.00e-59	209
C137_contig_4053_90	SARG|gi|748767925|ref|WP_040019608.1|	35.9	362	718	623	1.06e-58	208
C137_contig_4053_90	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.4	494	718	579	2.36e-58	206
C137_contig_4053_90	SARG|gi|664556405|ref|WP_031071225.1|	37.3	314	718	602	3.60e-58	206
C137_contig_4053_90	SARG|gi|695842130|ref|WP_032755430.1|	34.7	360	718	603	5.04e-58	206
C137_contig_4053_91	SARG|gb|AAK76136.1|ARO:3000025|patB	36.5	584	614	588	5.84e-119	364
C137_contig_4053_91	SARG|gb|CDO61516.1|ARO:3003949|efrB	55.0	329	614	362	8.66e-114	343
C137_contig_4053_91	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.0	516	614	664	1.21e-102	324
C137_contig_4053_91	SARG|gi|926351744|ref|WP_053683383.1|	35.2	537	614	648	5.05e-95	304
C137_contig_4053_91	SARG|gi|1045390184|ref|WP_065479071.1|	35.1	522	614	605	9.32e-95	302
C137_contig_4053_91	SARG|gi|921231571|ref|WP_053176464.1|	35.0	537	614	620	3.76e-94	301
C137_contig_4053_91	SARG|gi|917172177|ref|WP_051778889.1|	35.0	537	614	620	7.41e-94	300
C137_contig_4053_91	SARG|gi|662129758|ref|WP_030081404.1|	34.1	554	614	605	2.75e-93	298
C137_contig_4053_91	SARG|gi|919568551|ref|WP_052871170.1|	34.8	537	614	620	2.86e-93	298
C137_contig_4053_91	SARG|gi|497748188|ref|WP_010062372.1|	33.6	554	614	605	3.86e-93	298
C137_contig_4053_108	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.4	573	577	575	9.82e-116	354
C137_contig_4053_108	SARG|gb|AAK76137.1|ARO:3000024|patA	36.2	514	577	564	8.97e-99	310
C137_contig_4053_108	SARG|gi|1045390184|ref|WP_065479071.1|	29.3	569	577	605	8.67e-68	229
C137_contig_4053_108	SARG|gb|AAK76136.1|ARO:3000025|patB	28.3	580	577	588	1.68e-66	226
C137_contig_4053_108	SARG|gi|505420018|ref|WP_015607120.1|	29.4	568	577	603	3.15e-66	225
C137_contig_4053_108	SARG|gi|764446018|ref|WP_044369325.1|	29.2	569	577	605	4.56e-66	225
C137_contig_4053_108	SARG|gi|695842130|ref|WP_032755430.1|	29.4	568	577	603	8.49e-66	224
C137_contig_4053_108	SARG|gi|944009777|ref|WP_055601444.1|	30.3	574	577	628	1.38e-65	224
C137_contig_4053_108	SARG|gi|947982677|ref|WP_056642336.1|	29.6	570	577	626	1.84e-65	224
C137_contig_4053_108	SARG|gi|639892676|ref|WP_024755698.1|	29.6	570	577	631	2.02e-65	224
C137_contig_4053_109	SARG|gb|AAK76136.1|ARO:3000025|patB	40.2	517	607	588	1.02e-110	343
C137_contig_4053_109	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.1	504	607	664	4.13e-96	307
C137_contig_4053_109	SARG|gb|CDO61516.1|ARO:3003949|efrB	41.8	361	607	362	1.78e-83	265
C137_contig_4053_109	SARG|gi|948137056|ref|WP_056795395.1|	33.3	576	607	602	2.72e-83	271
C137_contig_4053_109	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.3	600	607	579	3.22e-82	268
C137_contig_4053_109	SARG|gi|695891735|ref|WP_032792824.1|	32.2	608	607	603	2.19e-81	266
C137_contig_4053_109	SARG|gi|663330365|ref|WP_030329892.1|	32.2	611	607	607	3.36e-81	266
C137_contig_4053_109	SARG|gi|951183771|ref|WP_057661487.1|	32.2	608	607	603	5.98e-81	265
C137_contig_4053_109	SARG|gi|493394434|ref|WP_006350564.1|	31.9	605	607	602	1.60e-80	264
C137_contig_4053_109	SARG|gi|827013130|ref|WP_047175495.1|	32.3	603	607	603	1.63e-80	264
C137_contig_4053_111	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	41.9	241	314	308	3.41e-50	167
C137_contig_4053_111	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	37.1	291	314	310	8.46e-48	161
C137_contig_6929_4	SARG|gb|AAV85982.1|ARO:3000535|macB	38.1	223	228	644	5.08e-45	157
C137_contig_6929_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.2	234	228	255	1.69e-44	148
C137_contig_6929_4	SARG|gi|823326845|ref|WP_047080664.1|	34.5	220	228	648	2.37e-37	136
C137_contig_6929_4	SARG|gi|1033064422|ref|WP_064375412.1|	35.0	220	228	648	3.25e-37	136
C137_contig_6929_4	SARG|gi|823302270|ref|WP_047057473.1|	34.5	220	228	648	4.46e-37	135
C137_contig_6929_4	SARG|gi|976146774|ref|WP_059305359.1|	34.5	220	228	648	4.46e-37	135
C137_contig_6929_4	SARG|gi|1022664304|ref|WP_063420886.1|	34.5	220	228	648	4.46e-37	135
C137_contig_6929_4	SARG|gi|823309640|ref|WP_047064288.1|	34.5	220	228	648	4.46e-37	135
C137_contig_6929_4	SARG|gi|505807117|ref|WP_015704872.1|	34.5	220	228	648	4.46e-37	135
C137_contig_6929_4	SARG|gi|518923394|ref|WP_020079269.1|	34.5	220	228	648	4.46e-37	135
C137_contig_6929_9	SARG|Q52360	22.1	674	694	641	1.56e-45	171
C137_contig_6929_9	SARG|Q08425	22.4	674	694	641	2.87e-45	170
C137_contig_6929_9	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	21.9	671	694	641	2.87e-45	170
C137_contig_6929_9	SARG|AAZ79478	21.9	671	694	657	3.44e-45	170
C137_contig_6929_9	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	22.4	674	694	657	3.44e-45	170
C137_contig_6929_9	SARG|Z21523.gene.p01	22.4	674	694	657	3.44e-45	170
C137_contig_6929_9	SARG|P70882	22.1	674	694	641	3.90e-45	170
C137_contig_6929_9	SARG|BAD46890	22.1	674	694	657	4.66e-45	170
C137_contig_6929_9	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	22.7	675	694	654	8.30e-45	169
C137_contig_6929_9	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	22.7	675	694	670	9.81e-45	169
C137_contig_6929_41	SARG|L42544.gene.p01	26.9	464	607	651	1.13e-28	120
C137_contig_6929_41	SARG|AAV80410	28.7	334	607	651	3.57e-28	118
C137_contig_6929_41	SARG|AJ514254.gene.p01	42.9	140	607	640	3.41e-27	115
C137_contig_6929_41	SARG|Q02652	43.3	141	607	639	7.75e-25	108
C137_contig_6929_41	megares|MEG_7148|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETM_1	38.8	147	607	644	1.85e-24	107
C137_contig_6929_41	SARG|AAK17952	40.7	140	607	639	4.27e-24	105
C137_contig_6929_41	SARG|ABN11268	40.7	140	607	639	4.27e-24	105
C137_contig_6929_41	SARG|ABG21123	40.0	140	607	639	5.67e-24	105
C137_contig_6929_41	SARG|AAY63943	40.0	140	607	639	5.67e-24	105
C137_contig_6929_41	SARG|gi|446614384|ref|WP_000691730.1|	40.0	140	607	639	5.67e-24	105
C137_contig_6929_47	SARG|ZP_04433866	53.8	275	289	288	1.79e-100	295
C137_contig_6929_47	SARG|ZP_03949893	53.8	275	289	288	1.79e-100	295
C137_contig_6929_47	SARG|ZP_03984017	53.5	275	289	288	3.60e-100	294
C137_contig_6929_47	SARG|ZP_03945515	54.5	279	289	291	2.28e-99	292
C137_contig_6929_47	SARG|ZP_03938934	53.6	278	289	288	2.37e-98	289
C137_contig_6929_47	SARG|ZP_03941859	53.2	278	289	288	9.59e-98	288
C137_contig_6929_47	SARG|ZP_04528247	53.6	280	289	279	1.16e-96	285
C137_contig_6929_47	SARG|YP_002929946	50.0	280	289	282	1.93e-88	264
C137_contig_6929_47	SARG|YP_002937728	49.3	286	289	289	2.77e-87	261
C137_contig_6929_47	SARG|ZP_03958019	50.0	288	289	317	3.85e-86	259
C137_contig_6929_51	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.9	247	479	365	6.40e-20	90.1
C137_contig_6929_51	CARD|gb|CYF42523.1|ARO:3004047|kdpD	33.1	172	479	885	3.79e-19	89.7
C137_contig_6929_51	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.7	266	479	370	9.75e-19	86.7
C137_contig_6929_51	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.6	237	479	367	2.44e-17	82.4
C137_contig_6929_51	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.6	237	479	368	2.46e-17	82.4
C137_contig_6929_51	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.8	227	479	359	5.51e-17	81.3
C137_contig_6929_51	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.9	193	479	381	8.81e-17	80.9
C137_contig_6929_51	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.9	193	479	381	8.81e-17	80.9
C137_contig_6929_51	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	193	479	381	1.18e-16	80.5
C137_contig_6929_51	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	193	479	381	1.18e-16	80.5
C137_contig_6929_52	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.6	223	220	231	9.46e-48	155
C137_contig_6929_52	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.9	223	220	232	1.95e-47	155
C137_contig_6929_52	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.9	218	220	228	6.93e-47	153
C137_contig_6929_52	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.4	218	220	219	1.21e-45	150
C137_contig_6929_52	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.5	228	220	229	2.54e-44	147
C137_contig_6929_52	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.0	230	220	231	1.07e-43	145
C137_contig_6929_52	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.6	228	220	231	1.20e-42	142
C137_contig_6929_52	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.9	218	220	220	2.49e-42	141
C137_contig_6929_52	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.6	228	220	231	4.77e-42	141
C137_contig_6929_52	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.9	215	220	219	4.84e-42	140
C137_contig_6929_53	SARG|gi|403023847|gb|EJY36064.1|	48.3	178	291	200	2.25e-54	174
C137_contig_6929_53	SARG|Q47746	48.9	178	291	268	4.24e-54	176
C137_contig_6929_53	SARG|gi|452996213|gb|AGG19398.1|	48.9	178	291	268	4.24e-54	176
C137_contig_6929_53	SARG|gi|498515090|ref|WP_010815297.1|	48.9	178	291	268	4.24e-54	176
C137_contig_6929_53	SARG|gi|452996227|gb|AGG19410.1|	48.3	178	291	252	1.06e-53	174
C137_contig_6929_53	SARG|gi|488259314|ref|WP_002330522.1|	48.3	178	291	268	1.68e-53	174
C137_contig_6929_53	SARG|gi|1036536100|emb|SAM71699.1|	48.3	178	291	268	1.68e-53	174
C137_contig_6929_53	SARG|gi|403219412|emb|CCJ27774.1|	48.9	180	291	268	1.68e-53	174
C137_contig_6929_53	SARG|KF823969.1.gene3.p01	48.3	178	291	268	1.68e-53	174
C137_contig_6929_53	NCBI|WP_063856783.1|1|1|vanXY-G2|vanXY-G2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G2|AMR|glycopeptide	43.0	135	291	254	1.67e-25	100
C137_contig_6929_109	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.5	562	587	575	4.34e-94	298
C137_contig_6929_109	SARG|gi|926351744|ref|WP_053683383.1|	32.3	586	587	648	3.84e-93	298
C137_contig_6929_109	SARG|gi|496018010|ref|WP_008742581.1|	32.7	588	587	623	4.09e-93	297
C137_contig_6929_109	SARG|gi|917155568|ref|WP_051762280.1|	32.4	586	587	620	7.47e-93	296
C137_contig_6929_109	SARG|gi|917166849|ref|WP_051773561.1|	32.3	586	587	620	2.89e-92	295
C137_contig_6929_109	SARG|gi|664556405|ref|WP_031071225.1|	32.3	582	587	602	3.63e-92	294
C137_contig_6929_109	SARG|gi|919568551|ref|WP_052871170.1|	32.1	586	587	620	4.06e-92	295
C137_contig_6929_109	SARG|gi|860594225|ref|WP_048475168.1|	31.8	578	587	620	4.06e-92	295
C137_contig_6929_109	SARG|gi|748767925|ref|WP_040019608.1|	32.7	575	587	623	4.66e-91	292
C137_contig_6929_109	SARG|gi|921231571|ref|WP_053176464.1|	31.7	586	587	620	6.07e-91	291
C137_contig_6929_113	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	35.1	211	563	373	2.49e-26	109
C137_contig_6929_114	SARG|gi|500194536|ref|WP_011867743.1|	29.0	300	302	306	2.08e-38	136
C137_contig_6929_118	SARG|gb|AAC75314.1|ARO:3003578|pmrF	32.4	111	331	322	1.99e-07	50.8
C137_contig_6929_122	SARG|gb|AAK76136.1|ARO:3000025|patB	36.3	573	581	588	2.62e-110	341
C137_contig_6929_122	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.0	520	581	664	8.56e-104	326
C137_contig_6929_122	SARG|gi|860594225|ref|WP_048475168.1|	33.2	584	581	620	4.51e-93	297
C137_contig_6929_122	SARG|gb|CDO61516.1|ARO:3003949|efrB	45.3	333	581	362	2.23e-92	287
C137_contig_6929_122	SARG|gi|558888514|ref|WP_023543283.1|	32.7	581	581	615	2.32e-91	292
C137_contig_6929_122	SARG|AF170880.4.gene1.p01	32.5	579	581	615	4.56e-91	291
C137_contig_6929_122	SARG|gi|772774655|ref|WP_045322518.1|	32.6	580	581	620	1.51e-89	288
C137_contig_6929_122	SARG|gi|926351744|ref|WP_053683383.1|	32.2	578	581	648	2.11e-89	288
C137_contig_6929_122	SARG|gi|926376632|ref|WP_053705806.1|	32.4	584	581	620	2.12e-89	287
C137_contig_6929_122	SARG|gi|917203192|ref|WP_051809904.1|	32.4	584	581	620	2.98e-89	287
C137_contig_6929_123	SARG|gb|WP_104671188.1|ARO:3003948|efrA	41.1	574	580	575	4.87e-139	414
C137_contig_6929_123	SARG|gb|AAK76137.1|ARO:3000024|patA	33.3	564	580	564	7.54e-102	318
C137_contig_6929_123	SARG|gi|926351744|ref|WP_053683383.1|	30.2	540	580	648	7.98e-68	231
C137_contig_6929_123	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	30.1	528	580	579	1.07e-66	226
C137_contig_6929_123	SARG|gi|943909899|ref|WP_055545300.1|	28.9	575	580	601	2.33e-66	226
C137_contig_6929_123	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.3	528	580	579	4.02e-66	224
C137_contig_6929_123	SARG|gi|919568551|ref|WP_052871170.1|	29.5	536	580	620	9.09e-66	224
C137_contig_6929_123	SARG|gi|917229923|ref|WP_051836635.1|	29.7	542	580	620	1.26e-65	224
C137_contig_6929_123	SARG|gi|860594225|ref|WP_048475168.1|	28.6	570	580	620	1.76e-65	224
C137_contig_6929_123	SARG|gi|921231571|ref|WP_053176464.1|	29.5	536	580	620	1.76e-65	224
C137_contig_6613_23	SARG|gi|445996719|ref|WP_000074574.1|	30.9	265	291	309	2.21e-32	120
C137_contig_6613_23	SARG|gi|542061059|gb|ERI11611.1|	33.6	226	291	316	2.54e-32	120
C137_contig_6613_23	SARG|gi|445996710|ref|WP_000074565.1|	31.6	234	291	309	1.63e-31	118
C137_contig_6613_23	SARG|gi|895736250|emb|COF64653.1|	31.6	234	291	309	2.28e-31	117
C137_contig_6613_23	SARG|gi|446110087|ref|WP_000187942.1|	31.6	234	291	309	2.28e-31	117
C137_contig_6613_23	SARG|gi|447057509|ref|WP_001134765.1|	32.4	225	291	309	2.28e-31	117
C137_contig_6613_23	SARG|gi|507035724|ref|WP_016107411.1|	32.4	225	291	309	3.17e-31	117
C137_contig_6613_23	SARG|gi|445996698|ref|WP_000074553.1|	32.4	225	291	309	3.17e-31	117
C137_contig_6613_23	SARG|gi|507055561|ref|WP_016126482.1|	32.0	225	291	309	4.43e-31	117
C137_contig_6613_23	SARG|gi|445996697|ref|WP_000074552.1|	32.4	225	291	309	4.43e-31	117
C137_contig_6613_24	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.1	246	287	343	3.90e-28	109
C137_contig_6613_24	SARG|gi|671541568|ref|WP_031525212.1|	35.1	211	287	648	4.80e-27	109
C137_contig_6613_24	SARG|gi|953808775|ref|WP_058042812.1|	31.8	245	287	608	3.80e-26	106
C137_contig_6613_24	SARG|gi|639216333|ref|WP_024554080.1|	33.2	223	287	648	1.01e-25	105
C137_contig_6613_24	SARG|gi|498115003|ref|WP_010429159.1|	33.8	213	287	646	1.37e-25	105
C137_contig_6613_24	SARG|gi|895898290|ref|WP_048999361.1|	33.8	213	287	646	3.40e-25	103
C137_contig_6613_24	SARG|gi|657888313|ref|WP_029592374.1|	33.2	223	287	648	3.41e-25	103
C137_contig_6613_24	SARG|gi|981224618|ref|WP_059445588.1|	32.2	245	287	646	4.61e-25	103
C137_contig_6613_24	SARG|gi|836585048|ref|WP_047742322.1|	32.3	235	287	646	6.24e-25	103
C137_contig_6613_24	SARG|gi|754493745|ref|WP_041910640.1|	33.3	213	287	646	8.46e-25	102
C137_contig_6613_25	SARG|gb|APB03216.1|ARO:3003982|LlmA	57.8	282	291	287	3.57e-127	362
C137_contig_6613_53	NCBI|WP_011860980.1|1|1|blaAHM-1|blaAHM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3-like_metallo-beta-lactamase_AHM-1|AMR|beta-lactam	30.6	245	315	304	5.10e-30	114
C137_contig_1612_37	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	44.0	680	647	703	1.33e-173	510
C137_contig_1612_52	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	30.2	484	687	633	2.05e-54	196
C137_contig_1612_58	SARG|gb|CAE00499.1|ARO:3003835|cdeA	31.6	431	467	441	1.25e-65	216
C137_contig_1612_84	SARG|gb|ABA71733.1|ARO:3002972|vanTG	36.1	379	397	712	8.21e-76	248
C137_contig_1612_84	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	35.6	374	397	712	3.82e-68	227
C137_contig_1612_84	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.5	379	397	711	5.47e-62	211
C137_contig_1612_84	SARG|AAY67970	34.0	379	397	698	2.29e-58	201
C137_contig_1612_84	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.6	381	397	700	2.35e-58	201
C137_contig_1612_84	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	36.5	337	397	700	2.35e-58	201
C137_contig_1612_84	SARG|AF162694.1.gene4.p01	34.0	379	397	698	4.40e-58	200
C137_contig_1612_84	SARG|gi|657686198|ref|WP_029487032.1|	34.0	379	397	698	4.40e-58	200
C137_contig_1612_84	SARG|gi|498467693|ref|WP_010773049.1|	32.8	375	397	700	1.67e-57	198
C137_contig_1612_84	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	35.6	337	397	700	1.59e-55	193
C137_contig_1612_100	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.2	227	224	232	4.26e-53	169
C137_contig_1612_100	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.3	226	224	231	6.63e-52	166
C137_contig_1612_100	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.5	220	224	219	3.74e-51	164
C137_contig_1612_100	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.6	229	224	232	1.55e-50	163
C137_contig_1612_100	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.6	229	224	232	1.55e-50	163
C137_contig_1612_100	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.0	228	224	229	1.60e-49	160
C137_contig_1612_100	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	222	224	219	2.40e-49	159
C137_contig_1612_100	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	222	224	220	2.47e-49	159
C137_contig_1612_100	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	222	224	220	3.49e-49	159
C137_contig_1612_100	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.3	222	224	219	1.92e-48	157
C137_contig_1612_101	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.3	246	514	381	1.13e-31	124
C137_contig_1612_101	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.3	246	514	381	1.13e-31	124
C137_contig_1612_101	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.0	246	514	381	1.02e-30	122
C137_contig_1612_101	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.0	246	514	381	1.02e-30	122
C137_contig_1612_101	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.0	246	514	381	2.59e-30	120
C137_contig_1612_101	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.0	246	514	381	2.59e-30	120
C137_contig_1612_101	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.0	246	514	381	4.83e-30	120
C137_contig_1612_101	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.0	246	514	381	4.83e-30	120
C137_contig_1612_101	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.6	246	514	381	1.23e-29	119
C137_contig_1612_101	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.6	246	514	381	1.23e-29	119
C137_contig_1612_147	NCBI|WP_011860980.1|1|1|blaAHM-1|blaAHM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3-like_metallo-beta-lactamase_AHM-1|AMR|beta-lactam	30.3	228	286	304	3.78e-37	132
C137_contig_736_19	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	68.4	57	63	416	3.12e-23	89.0
C137_contig_736_26	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	27.7	358	2465	556	2.55e-30	127
C137_contig_736_42	SARG|gi|542061059|gb|ERI11611.1|	45.7	302	302	316	1.13e-88	266
C137_contig_736_42	SARG|P42332	43.7	302	302	306	4.30e-86	259
C137_contig_736_42	SARG|ABB80128	43.7	302	302	306	6.09e-86	259
C137_contig_736_42	SARG|gi|500194536|ref|WP_011867743.1|	45.4	302	302	306	6.09e-86	259
C137_contig_736_42	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	43.4	302	302	306	1.22e-85	258
C137_contig_736_42	SARG|gi|510143239|gb|AGN36970.1|	43.4	302	302	313	1.52e-85	258
C137_contig_736_42	SARG|gi|447195835|ref|WP_001273091.1|	45.4	302	302	306	4.91e-85	256
C137_contig_736_42	SARG|AAD21213	43.4	302	302	306	4.91e-85	256
C137_contig_736_42	SARG|gi|447195836|ref|WP_001273092.1|	45.0	302	302	306	1.39e-84	255
C137_contig_736_42	SARG|gi|500448961|gb|EOP61695.1|	44.4	302	302	306	1.97e-84	255
C137_contig_736_56	SARG|AB116646.1.gene1.p01	30.7	88	169	157	3.47e-09	52.0
C137_contig_736_56	NCBI|WP_043911783.1|1|1|aac(6')_Strep|aac(6')_Strep|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	29.5	88	169	157	1.28e-08	50.4
C137_contig_736_56	NCBI|WP_053638058.1|1|1|aacA-STR-7|aacA-STR-7|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	27.5	91	169	157	3.40e-08	49.3
C137_contig_736_56	NCBI|WP_031084431.1|1|1|aacA-STR-7|aacA-STR-7|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	27.5	91	169	157	3.40e-08	49.3
C137_contig_736_56	NCBI|WP_030403494.1|1|1|aacA-STR-7|aacA-STR-7|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	27.5	91	169	157	3.40e-08	49.3
C137_contig_736_68	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	39.3	201	241	255	2.56e-37	130
C137_contig_736_69	SARG|gi|686113687|ref|WP_031764317.1|	19.9	437	450	451	6.07e-13	69.3
C137_contig_736_70	SARG|AUI09862.1	44.0	277	276	287	4.41e-77	234
C137_contig_736_70	SARG|AJ459418.gene.p01	35.2	261	276	263	1.11e-48	161
C137_contig_736_70	SARG|gi|970263436|ref|WP_058647620.1|	35.2	261	276	263	1.57e-48	160
C137_contig_736_70	SARG|gi|499290101|ref|WP_010981367.1|	30.1	272	276	283	1.54e-34	125
C137_contig_736_70	SARG|gi|499589362|ref|WP_011270145.1|	29.8	272	276	283	3.02e-34	124
C137_contig_736_70	SARG|gi|504873101|ref|WP_015060203.1|	30.8	273	276	283	4.24e-34	124
C137_contig_736_70	SARG|gi|553729091|ref|WP_023063817.1|	29.4	262	276	271	4.53e-34	123
C137_contig_736_70	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	29.4	262	276	271	4.53e-34	123
C137_contig_736_70	SARG|gi|487670925|ref|WP_001756235.1|	29.4	262	276	271	6.34e-34	123
C137_contig_736_70	SARG|gi|638947703|ref|WP_024439711.1|	29.4	262	276	271	6.34e-34	123
C137_contig_736_87	SARG|P43433	30.9	188	293	311	1.28e-18	83.2
C137_contig_736_87	SARG|AAA22075	30.9	188	293	340	2.08e-17	80.1
C137_contig_736_87	SARG|AF319779.2.orf0.gene.p01	26.9	186	293	266	9.27e-15	71.6
C137_contig_736_87	SARG|ZP_04543635	25.7	187	293	266	1.73e-14	70.9
C137_contig_736_87	SARG|L22689.1.gene1.p01	28.5	186	293	257	2.12e-14	70.5
C137_contig_736_87	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	25.4	197	293	304	3.43e-14	70.5
C137_contig_736_89	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.5	232	235	232	6.13e-69	210
C137_contig_736_89	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.1	232	235	232	1.74e-68	209
C137_contig_736_89	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.5	233	235	233	2.55e-68	209
C137_contig_736_89	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.0	225	235	231	1.11e-66	204
C137_contig_736_89	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.2	229	235	229	2.38e-65	201
C137_contig_736_89	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	42.7	232	235	239	1.31e-64	199
C137_contig_736_89	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	43.0	235	235	235	2.32e-64	199
C137_contig_736_89	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.2	232	235	231	8.25e-64	197
C137_contig_736_89	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.8	232	235	231	2.34e-63	196
C137_contig_736_89	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.4	224	235	232	3.42e-63	196
C137_contig_736_90	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	31.4	287	681	392	2.87e-32	128
C137_contig_736_90	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.5	274	681	365	1.50e-31	125
C137_contig_736_90	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.7	286	681	380	1.21e-30	123
C137_contig_736_90	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.7	286	681	380	1.21e-30	123
C137_contig_736_90	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.3	304	681	367	3.24e-30	121
C137_contig_736_90	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.3	289	681	381	1.86e-29	119
C137_contig_736_90	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.3	289	681	381	1.86e-29	119
C137_contig_736_90	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.6	290	681	368	1.67e-28	116
C137_contig_736_90	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	252	681	381	2.06e-28	116
C137_contig_736_90	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	252	681	381	2.06e-28	116
C137_contig_736_109	SARG|AF277571.gene.p01	44.4	360	364	343	3.03e-90	273
C137_contig_736_109	SARG|ACQ66105	43.6	360	364	342	8.32e-90	272
C137_contig_736_109	SARG|gi|1028100561|ref|WP_063856696.1|	43.3	356	364	349	1.46e-89	272
C137_contig_736_109	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	44.6	361	364	341	2.28e-89	271
C137_contig_736_109	SARG|gi|511041762|ref|WP_016295754.1|	44.4	360	364	343	2.43e-89	271
C137_contig_736_109	NCBI|WP_018211347.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	44.0	361	364	345	2.58e-89	271
C137_contig_736_109	SARG|DQ212986.1.gene8.p01	43.1	357	364	349	2.93e-89	271
C137_contig_736_109	SARG|KF823969.1.gene6.p01	43.6	360	364	342	3.33e-89	271
C137_contig_736_109	SARG|gi|405945042|pdb|4FU0|A	43.1	357	364	357	3.75e-89	271
C137_contig_736_109	NCBI|WP_016331865.1|1|1|vanA-Ao2|vanA-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanA-Ao2|AMR|glycopeptide	43.0	358	364	348	5.67e-89	270
C137_contig_4137_8	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	26.4	803	875	1024	2.93e-80	279
C137_contig_4137_8	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	26.4	803	875	1024	2.93e-80	279
C137_contig_4137_8	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	26.4	803	875	1024	1.03e-79	277
C137_contig_4137_8	SARG|gb|CAA53189|ARO:3000521|mupA	26.4	803	875	1024	1.03e-79	277
C137_contig_4137_8	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	26.4	614	875	1033	4.61e-67	241
C137_contig_4137_8	SARG|gb|AEY83581|ARO:3000510|mupB	26.4	614	875	1033	4.61e-67	241
C137_contig_4137_13	SARG|gi|740152780|ref|WP_037997109.1|	34.4	215	317	322	3.78e-27	107
C137_contig_4137_13	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.3	215	317	323	3.84e-27	107
C137_contig_4137_13	SARG|YP_002333394	35.3	215	317	323	7.37e-27	106
C137_contig_4137_13	SARG|AF310956.2.gene5.p01	35.3	215	317	323	1.02e-26	106
C137_contig_4137_13	SARG|KF478993.1.gene2.p01	32.1	215	317	350	7.38e-25	101
C137_contig_4137_13	SARG|AAF72362	34.7	213	317	323	1.82e-24	100
C137_contig_4137_26	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.6	268	489	370	2.04e-29	117
C137_contig_4137_26	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.9	286	489	365	4.27e-28	114
C137_contig_4137_26	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.0	228	489	381	1.38e-27	112
C137_contig_4137_26	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.0	228	489	381	1.38e-27	112
C137_contig_4137_26	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	228	489	381	2.21e-26	109
C137_contig_4137_26	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	228	489	381	2.21e-26	109
C137_contig_4137_26	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	227	489	381	1.39e-25	107
C137_contig_4137_26	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.5	227	489	381	1.39e-25	107
C137_contig_4137_26	CARD|gb|ABD30512.1|ARO:3000839|arlS	24.5	343	489	451	6.46e-23	100
C137_contig_4137_26	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.4	214	489	367	1.72e-22	97.8
C137_contig_4137_27	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.9	217	219	219	8.93e-51	163
C137_contig_4137_27	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.2	217	219	228	2.10e-48	157
C137_contig_4137_27	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.5	216	219	219	3.67e-47	154
C137_contig_4137_27	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.5	216	219	220	3.77e-47	154
C137_contig_4137_27	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.5	216	219	220	1.07e-46	152
C137_contig_4137_27	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.0	216	219	219	2.93e-46	151
C137_contig_4137_27	SARG|ZP_02848503	36.6	216	219	221	1.97e-44	147
C137_contig_4137_27	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.6	216	219	220	2.70e-44	146
C137_contig_4137_27	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.9	220	219	223	7.39e-42	140
C137_contig_4137_27	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	225	219	231	5.15e-41	138
C137_contig_4143_30	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.1	688	803	1024	2.74e-29	124
C137_contig_4143_30	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.1	688	803	1024	2.74e-29	124
C137_contig_4143_30	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.1	688	803	1024	2.74e-29	124
C137_contig_4143_30	SARG|gb|CAA53189|ARO:3000521|mupA	23.1	688	803	1024	2.74e-29	124
C137_contig_4143_30	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.2	679	803	1033	1.46e-28	122
C137_contig_4143_30	SARG|gb|AEY83581|ARO:3000510|mupB	22.2	679	803	1033	1.46e-28	122
C137_contig_4143_30	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.9	691	803	1107	1.42e-14	77.0
C137_contig_4143_30	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.9	691	803	1107	1.42e-14	77.0
C137_contig_4143_39	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.1	113	260	228	1.15e-08	53.1
C137_contig_4143_87	SARG|gi|1035706844|ref|WP_064548272.1|	36.4	77	748	648	3.48e-08	55.8
C137_contig_2540_37	SARG|gi|1031824807|ref|WP_064152164.1|	35.7	112	826	646	4.43e-09	58.9
C137_contig_2540_37	SARG|gi|1044231927|emb|SBX14918.1|	34.8	112	826	646	5.83e-09	58.5
C137_contig_2540_37	SARG|gi|694113840|ref|WP_032455777.1|	34.8	112	826	646	7.67e-09	58.2
C137_contig_2540_37	SARG|gi|556195652|ref|WP_023279140.1|	34.8	112	826	646	7.67e-09	58.2
C137_contig_2540_37	SARG|gi|490295685|ref|WP_004191149.1|	34.8	112	826	646	7.67e-09	58.2
C137_contig_2540_37	SARG|gi|852125444|ref|WP_048290339.1|	34.8	112	826	646	7.67e-09	58.2
C137_contig_2540_37	SARG|gi|556476567|ref|WP_023328168.1|	34.8	112	826	641	1.01e-08	57.8
C137_contig_2540_37	SARG|gi|895895864|ref|WP_048997630.1|	34.8	112	826	644	1.01e-08	57.8
C137_contig_2540_37	SARG|gi|1031835425|ref|WP_064161077.1|	34.8	112	826	646	1.01e-08	57.8
C137_contig_2540_37	SARG|gi|757709471|ref|WP_042938492.1|	34.8	112	826	646	1.01e-08	57.8
C137_contig_2540_59	SARG|gi|695842130|ref|WP_032755430.1|	35.9	365	553	603	2.49e-58	203
C137_contig_2540_59	SARG|gi|505420018|ref|WP_015607120.1|	35.9	365	553	603	2.49e-58	203
C137_contig_2540_59	SARG|gi|764446018|ref|WP_044369325.1|	36.4	365	553	605	2.58e-58	203
C137_contig_2540_59	SARG|gi|1045390184|ref|WP_065479071.1|	37.2	368	553	605	2.58e-58	203
C137_contig_2540_59	SARG|gi|664180077|ref|WP_030714054.1|	36.4	365	553	605	2.58e-58	203
C137_contig_2540_59	SARG|gi|664085850|ref|WP_030624018.1|	36.4	363	553	605	3.58e-58	203
C137_contig_2540_59	SARG|gi|695865802|ref|WP_032778631.1|	36.2	365	553	605	3.58e-58	203
C137_contig_2540_59	SARG|gi|662129758|ref|WP_030081404.1|	36.4	363	553	605	3.58e-58	203
C137_contig_2540_59	SARG|gi|702897513|ref|WP_033300957.1|	36.8	356	553	601	1.23e-57	201
C137_contig_2540_59	SARG|gi|948137056|ref|WP_056795395.1|	36.3	364	553	602	1.73e-57	201
C137_contig_2540_60	SARG|gi|664556405|ref|WP_031071225.1|	35.6	267	581	602	1.38e-42	160
C137_contig_2540_60	SARG|gi|860594225|ref|WP_048475168.1|	35.1	265	581	620	2.29e-42	160
C137_contig_2540_60	SARG|gi|764446018|ref|WP_044369325.1|	33.9	301	581	605	2.65e-42	159
C137_contig_2540_60	SARG|gi|943896259|ref|WP_055534530.1|	35.3	275	581	601	3.46e-42	159
C137_contig_2540_60	SARG|gi|951183771|ref|WP_057661487.1|	33.9	301	581	603	3.54e-42	159
C137_contig_2540_60	SARG|gi|664317010|ref|WP_030845774.1|	34.6	301	581	605	3.62e-42	159
C137_contig_2540_60	SARG|gi|663286402|ref|WP_030292859.1|	34.6	301	581	605	3.62e-42	159
C137_contig_2540_60	SARG|gi|663342223|ref|WP_030341347.1|	34.6	301	581	605	3.62e-42	159
C137_contig_2540_60	SARG|gi|759527374|ref|WP_043247487.1|	34.6	301	581	605	3.62e-42	159
C137_contig_2540_60	SARG|gi|664194237|ref|WP_030727956.1|	34.6	301	581	605	3.62e-42	159
C137_contig_2540_62	SARG|M80346.gene.p01	22.9	201	259	551	1.13e-07	51.2
C137_contig_2540_62	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	22.9	201	259	551	1.13e-07	51.2
C137_contig_1506_20	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.7	72	527	235	1.73e-08	54.3
C137_contig_1506_20	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.9	68	527	231	2.51e-06	47.8
C137_contig_1506_20	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.9	68	527	231	2.51e-06	47.8
C137_contig_1506_20	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.9	68	527	231	3.36e-06	47.4
C137_contig_1506_20	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.4	68	527	231	4.51e-06	47.0
C137_contig_1506_20	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.9	70	527	228	5.89e-06	46.6
C137_contig_1506_35	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	37.5	72	245	301	1.38e-09	56.2
C137_contig_1506_40	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.1	203	222	204	1.62e-18	79.3
C137_contig_1506_40	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.3	115	222	228	5.46e-12	62.0
C137_contig_1506_40	CARD|gb|ADM92605.1|ARO:3000553|adeR	24.7	215	222	247	6.29e-09	53.5
C137_contig_1506_40	CARD|gb|ATC67679.1|ARO:3000838|arlR	23.3	215	222	219	1.71e-06	46.2
C137_contig_1506_102	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.7	202	211	204	4.46e-20	83.2
C137_contig_1506_102	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.1	103	211	228	6.32e-09	53.1
C137_contig_1506_104	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	34.5	313	311	343	1.14e-56	185
C137_contig_1506_104	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	33.7	309	311	325	1.24e-50	169
C137_contig_1506_104	SARG|gb|AAA26793|ARO:3003748|oleC	33.9	307	311	325	2.45e-50	168
C137_contig_1506_104	SARG|gi|542061059|gb|ERI11611.1|	36.5	222	311	316	4.36e-39	139
C137_contig_1506_104	SARG|YP_001373621	30.5	308	311	318	3.60e-37	134
C137_contig_1506_104	SARG|P42332	32.9	210	311	306	8.59e-34	124
C137_contig_1506_104	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	32.9	210	311	306	8.59e-34	124
C137_contig_1506_104	SARG|gi|510143239|gb|AGN36970.1|	32.9	210	311	313	9.94e-34	124
C137_contig_1506_104	SARG|ABB80128	32.9	210	311	306	1.20e-33	124
C137_contig_1506_104	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	27.9	326	311	351	2.08e-33	124
C137_contig_1506_113	CARD|gb|AAC75136.1|ARO:3000793|mdtB	26.3	839	1313	1040	5.21e-62	230
C137_contig_1506_113	SARG|gb|AAG05914|ARO:3004075|MuxC	25.2	846	1313	1036	1.40e-57	216
C137_contig_1506_113	CARD|gb|AAC75137.1|ARO:3000794|mdtC	25.5	836	1313	1025	3.91e-56	211
C137_contig_1506_113	SARG|gb|AAG05915.1|ARO:3004074|MuxB	25.2	834	1313	1043	7.58e-56	211
C137_contig_1506_113	SARG|gb|BAE06006.1|ARO:3003705|mexN	26.3	856	1313	1036	2.84e-54	206
C137_contig_1506_113	SARG|gb|CAH14033.1|ARO:3004100|LpeB	26.7	854	1313	1014	3.36e-54	205
C137_contig_1506_113	SARG|YP_348488	25.3	830	1313	1043	9.04e-54	204
C137_contig_1506_113	SARG|gi|852273548|ref|WP_048328542.1|	25.6	840	1313	1043	7.51e-51	195
C137_contig_1506_113	ResF|tmexD4_1_CP091084_1	25.0	831	1313	1044	2.15e-49	190
C137_contig_1506_113	SARG|gi|757680562|ref|WP_042911120.1|	25.8	827	1313	1043	2.83e-49	190
C137_contig_1506_126	SARG|gi|488374619|ref|WP_002444004.1|	23.2	263	433	452	9.73e-06	46.6
C137_contig_1506_134	SARG|Q02652	50.4	115	126	639	8.35e-31	114
C137_contig_1506_134	SARG|YP_002850805	46.5	114	126	652	1.04e-29	110
C137_contig_1506_134	SARG|CAA37477	51.8	114	126	663	1.44e-29	110
C137_contig_1506_134	SARG|CAV31157	49.1	114	126	639	1.91e-29	110
C137_contig_1506_134	SARG|AAS45561	49.1	114	126	639	1.91e-29	110
C137_contig_1506_134	SARG|L42544.gene.p01	47.4	114	126	651	1.94e-29	110
C137_contig_1506_134	SARG|AAV80410	47.4	114	126	651	1.94e-29	110
C137_contig_1506_134	megares|MEG_7148|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETM_1	50.0	114	126	644	2.63e-29	109
C137_contig_1506_134	SARG|ZP_03989103	50.9	114	126	639	3.58e-29	109
C137_contig_1506_134	SARG|AAK17952	49.1	114	126	639	3.58e-29	109
C137_contig_1506_145	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.3	224	230	231	4.50e-62	192
C137_contig_1506_145	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.2	221	230	228	3.31e-61	190
C137_contig_1506_145	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.0	230	230	232	7.50e-61	189
C137_contig_1506_145	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.0	230	230	232	7.50e-61	189
C137_contig_1506_145	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.1	228	230	233	1.62e-57	181
C137_contig_1506_145	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	225	230	232	3.15e-57	180
C137_contig_1506_145	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.2	227	230	231	1.23e-56	179
C137_contig_1506_145	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.3	231	230	231	1.73e-56	178
C137_contig_1506_145	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.2	219	230	219	2.42e-56	177
C137_contig_1506_145	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.9	230	230	239	3.12e-56	178
C137_contig_1506_146	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.0	262	475	370	5.96e-38	141
C137_contig_1506_146	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.2	277	475	365	1.38e-36	137
C137_contig_1506_146	CARD|gb|CYF42523.1|ARO:3004047|kdpD	26.3	240	475	885	3.45e-17	83.6
C137_contig_1506_183	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	27.9	276	464	593	1.82e-21	96.3
C137_contig_1506_183	SARG|AAX35723	23.0	387	464	665	1.10e-16	81.6
C137_contig_1506_183	NCBI|WP_063852700.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	24.3	333	464	668	1.46e-16	81.3
C137_contig_1506_183	megares|MEG_3788|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.3	317	464	668	2.58e-16	80.5
C137_contig_1506_183	megares|MEG_3789|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.2	335	464	668	2.58e-16	80.5
C137_contig_1506_183	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.7	312	464	666	4.54e-16	79.7
C137_contig_1506_183	SARG|gi|686196719|ref|WP_031807381.1|	24.2	335	464	668	4.55e-16	79.7
C137_contig_1506_183	NCBI|WP_063852694.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	24.0	333	464	668	4.55e-16	79.7
C137_contig_1506_183	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	26.1	341	464	664	6.01e-16	79.3
C137_contig_1506_183	megares|MEG_3793|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.8	335	464	668	6.04e-16	79.3
C137_contig_1506_243	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.5	227	236	228	6.80e-65	200
C137_contig_1506_243	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.8	232	236	231	1.12e-50	164
C137_contig_1506_243	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.9	229	236	232	6.52e-50	162
C137_contig_1506_243	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.9	229	236	232	6.52e-50	162
C137_contig_1506_243	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.8	232	236	231	8.95e-50	161
C137_contig_1506_243	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.8	232	236	231	8.95e-50	161
C137_contig_1506_243	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.1	232	236	231	1.27e-49	161
C137_contig_1506_243	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.3	228	236	231	3.57e-49	160
C137_contig_1506_243	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	231	236	231	2.85e-48	157
C137_contig_1506_243	CARD|gb|AAG05188.1|ARO:3005068|ParR	39.7	224	236	235	3.19e-48	157
C137_contig_1506_244	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.9	232	582	381	3.46e-35	135
C137_contig_1506_244	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.9	232	582	381	3.46e-35	135
C137_contig_1506_244	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.2	232	582	381	1.77e-32	127
C137_contig_1506_244	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.2	232	582	381	1.77e-32	127
C137_contig_1506_244	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.6	232	582	381	8.33e-32	125
C137_contig_1506_244	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.9	230	582	381	8.33e-32	125
C137_contig_1506_244	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.6	232	582	381	8.33e-32	125
C137_contig_1506_244	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.9	230	582	381	8.33e-32	125
C137_contig_1506_244	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.0	230	582	381	5.31e-31	123
C137_contig_1506_244	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.0	230	582	381	5.31e-31	123
C137_contig_1506_246	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.5	561	581	575	6.72e-107	332
C137_contig_1506_246	SARG|gb|AAK76137.1|ARO:3000024|patA	33.9	569	581	564	6.50e-96	303
C137_contig_1506_246	SARG|gi|516574297|ref|WP_017949361.1|	43.5	262	581	620	2.45e-62	215
C137_contig_1506_246	SARG|gi|926400371|ref|WP_053728483.1|	42.7	262	581	603	9.19e-62	213
C137_contig_1506_246	SARG|gi|739906046|ref|WP_037756452.1|	42.7	262	581	620	1.74e-61	213
C137_contig_1506_246	SARG|gi|1011969930|ref|WP_062776015.1|	42.7	262	581	601	3.28e-61	212
C137_contig_1506_246	SARG|gi|748767925|ref|WP_040019608.1|	42.7	262	581	623	9.38e-61	211
C137_contig_1506_246	SARG|gi|944470764|ref|WP_055701183.1|	42.4	262	581	601	3.23e-60	209
C137_contig_1506_246	SARG|gi|943938624|ref|WP_055567802.1|	42.4	262	581	602	3.29e-60	209
C137_contig_1506_246	SARG|gi|497748188|ref|WP_010062372.1|	41.2	262	581	605	4.82e-60	209
C137_contig_1506_247	SARG|gb|AAK76136.1|ARO:3000025|patB	32.7	584	631	588	1.99e-93	298
C137_contig_1506_247	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.4	554	631	664	1.04e-82	272
C137_contig_1506_247	SARG|gi|1033217078|gb|OAR27197.1|	29.5	630	631	601	6.65e-73	244
C137_contig_1506_247	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.8	528	631	582	6.22e-72	241
C137_contig_1506_247	SARG|gi|860594225|ref|WP_048475168.1|	31.3	562	631	620	1.01e-71	242
C137_contig_1506_247	SARG|gi|664556405|ref|WP_031071225.1|	30.2	569	631	602	1.86e-71	241
C137_contig_1506_247	SARG|gi|827013130|ref|WP_047175495.1|	30.6	568	631	603	3.69e-71	240
C137_contig_1506_247	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.8	622	631	579	4.26e-71	239
C137_contig_1506_247	SARG|gi|951183771|ref|WP_057661487.1|	30.6	569	631	603	7.15e-71	239
C137_contig_1506_247	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	31.0	630	631	578	1.13e-70	238
C137_contig_1506_250	SARG|gi|746609237|ref|WP_039635344.1|	28.7	223	390	322	2.71e-15	75.1
C137_contig_1506_250	SARG|AF155139.2.gene6.p01	27.8	223	390	322	1.62e-14	72.8
C137_contig_1506_250	SARG|DQ018711.1.gene4.p01	27.8	227	390	322	2.94e-14	72.0
C137_contig_1506_250	SARG|gi|738848198|ref|WP_036737307.1|	26.9	227	390	323	9.70e-14	70.5
C137_contig_1506_250	SARG|NP_878015	26.7	225	390	322	2.34e-13	69.3
C137_contig_1506_250	SARG|gi|737310392|ref|WP_035293250.1|	26.9	227	390	323	7.66e-13	67.8
C137_contig_1506_250	SARG|AY082011.1.gene6.p01	26.5	230	390	323	1.85e-12	66.6
C137_contig_1506_250	SARG|gi|552942232|ref|WP_023043160.1|	26.5	230	390	323	3.33e-12	65.9
C137_contig_1506_266	megares|MEG_4107|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	37.9	195	277	283	1.47e-28	109
C137_contig_1506_266	SARG|gb|CAB37345.2|ARO:3004592|erm(32)	34.3	233	277	280	2.70e-28	108
C137_contig_1506_266	SARG|gb|AAD12162.1|ARO:3001299|tlrB	34.3	233	277	280	5.26e-28	107
C137_contig_1506_275	SARG|gi|500194536|ref|WP_011867743.1|	30.5	197	243	306	2.00e-25	100
C137_contig_1506_275	SARG|YP_001571041	30.4	184	243	648	2.96e-18	82.4
C137_contig_1506_275	SARG|gi|960873409|ref|WP_058345546.1|	30.4	184	243	648	2.96e-18	82.4
C137_contig_1506_275	SARG|gi|817602846|ref|WP_046596462.1|	30.4	184	243	648	5.43e-18	81.6
C137_contig_1506_275	SARG|gi|740610794|ref|WP_038396317.1|	30.4	184	243	648	7.35e-18	81.3
C137_contig_1506_275	SARG|gi|912614197|ref|WP_050196089.1|	31.0	184	243	648	1.35e-17	80.5
C137_contig_1506_275	SARG|gi|923061916|ref|WP_053445667.1|	29.4	204	243	648	1.35e-17	80.5
C137_contig_1506_275	SARG|gi|487407385|ref|WP_001675419.1|	31.0	184	243	648	1.82e-17	80.1
C137_contig_1506_275	SARG|gi|487661511|ref|WP_001751648.1|	31.0	184	243	648	1.82e-17	80.1
C137_contig_1506_275	SARG|gi|446048030|ref|WP_000125885.1|	31.0	184	243	648	1.82e-17	80.1
C137_contig_1506_286	SARG|Q47746	31.4	175	301	268	2.60e-22	92.8
C137_contig_1506_286	SARG|gi|403023847|gb|EJY36064.1|	30.3	175	301	200	4.80e-22	90.5
C137_contig_1506_286	SARG|gi|452996213|gb|AGG19398.1|	30.9	175	301	268	9.53e-22	91.3
C137_contig_1506_286	SARG|gi|498515090|ref|WP_010815297.1|	30.9	175	301	268	9.53e-22	91.3
C137_contig_1506_286	SARG|gi|452996227|gb|AGG19410.1|	30.3	175	301	252	1.38e-21	90.5
C137_contig_1506_286	SARG|gi|488259314|ref|WP_002330522.1|	30.3	175	301	268	1.82e-21	90.5
C137_contig_1506_286	SARG|gi|1036536100|emb|SAM71699.1|	30.3	175	301	268	1.82e-21	90.5
C137_contig_1506_286	SARG|KF823969.1.gene3.p01	30.3	175	301	268	1.82e-21	90.5
C137_contig_1506_286	SARG|gi|403219412|emb|CCJ27774.1|	29.7	175	301	268	2.41e-20	87.4
C137_contig_1506_286	SARG|FJ349556.1.gene4.p01	38.3	94	301	233	4.81e-15	72.0
C137_contig_1506_297	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	55.7	1205	1244	1162	0.0	1239
C137_contig_1506_297	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	53.6	1242	1244	1186	0.0	1207
C137_contig_1506_297	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	53.6	1242	1244	1186	0.0	1207
C137_contig_1506_301	SARG|NP_348076	26.8	675	694	652	9.53e-82	271
C137_contig_1506_301	SARG|L42544.gene.p01	28.4	670	694	651	1.85e-80	268
C137_contig_1506_301	SARG|AAV80410	28.2	670	694	651	9.68e-80	266
C137_contig_1506_301	SARG|YP_002850805	27.3	675	694	652	2.67e-79	265
C137_contig_1506_301	SARG|ZP_02952732	27.0	675	694	652	1.41e-77	260
C137_contig_1506_301	SARG|ZP_02632674	27.0	675	694	660	1.67e-77	260
C137_contig_1506_301	SARG|L20800.gene.p01	27.0	675	694	652	3.80e-77	259
C137_contig_1506_301	SARG|AY485126.gene.p01	27.0	682	694	639	5.65e-73	247
C137_contig_1506_301	SARG|YP_594556	27.7	683	694	639	2.10e-72	246
C137_contig_1506_301	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.0	682	694	629	3.29e-72	245
C137_contig_1506_302	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.7	130	401	639	6.32e-17	81.6
C137_contig_4136_11	SARG|gi|542061059|gb|ERI11611.1|	33.8	219	290	316	9.38e-32	119
C137_contig_4136_11	SARG|gi|447195835|ref|WP_001273091.1|	35.5	211	290	306	2.19e-29	112
C137_contig_4136_11	SARG|gi|447195836|ref|WP_001273092.1|	35.1	211	290	306	5.92e-29	111
C137_contig_4136_11	SARG|gi|507055561|ref|WP_016126482.1|	32.0	219	290	309	6.26e-29	111
C137_contig_4136_11	SARG|gi|488053456|ref|WP_002124853.1|	32.0	219	290	309	8.71e-29	110
C137_contig_4136_11	SARG|gi|447057509|ref|WP_001134765.1|	32.4	219	290	309	8.71e-29	110
C137_contig_4136_11	SARG|gi|445996722|ref|WP_000074577.1|	33.3	219	290	309	8.71e-29	110
C137_contig_4136_11	SARG|gi|445996723|ref|WP_000074578.1|	32.9	219	290	309	1.21e-28	110
C137_contig_4136_11	SARG|gi|488068784|ref|WP_002140181.1|	29.0	279	290	309	1.21e-28	110
C137_contig_4136_11	SARG|gi|488067981|ref|WP_002139378.1|	32.0	219	290	309	1.69e-28	110
C137_contig_4136_13	CARD|gb|BAB38260.1|ARO:3000830|cpxA	27.2	283	406	457	2.56e-17	82.4
C137_contig_4136_13	CARD|gb|ADM92606.1|ARO:3000549|adeS	25.6	285	406	361	1.42e-12	67.4
C137_contig_4136_14	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.8	224	224	231	1.06e-50	163
C137_contig_4136_14	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.0	223	224	232	1.09e-50	163
C137_contig_4136_14	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.7	232	224	231	2.71e-48	157
C137_contig_4136_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.7	229	224	231	7.65e-48	156
C137_contig_4136_14	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.2	232	224	231	4.31e-47	154
C137_contig_4136_14	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.8	232	224	231	6.10e-47	154
C137_contig_4136_14	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.6	232	224	232	2.50e-46	152
C137_contig_4136_14	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.1	223	224	229	4.59e-46	151
C137_contig_4136_14	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	232	224	231	4.85e-46	151
C137_contig_4136_14	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.2	232	224	232	7.05e-46	151
C137_contig_4136_27	SARG|gb|CAE00499.1|ARO:3003835|cdeA	39.5	440	444	441	3.60e-101	308
C137_contig_4136_29	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.2	119	537	219	1.47e-08	54.3
C137_contig_4136_29	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.4	112	537	228	2.21e-08	53.9
C137_contig_4136_29	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.4	85	537	247	2.83e-07	50.8
C137_contig_4136_29	CARD|gb|BAB36671.1|ARO:3000832|evgA	20.5	117	537	204	6.42e-06	46.2
C137_contig_4136_37	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.5	117	515	219	2.32e-09	56.6
C137_contig_4136_37	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	28.4	116	515	228	6.35e-09	55.5
C137_contig_4136_37	CARD|gb|BAB36671.1|ARO:3000832|evgA	23.1	117	515	204	1.37e-06	48.1
C137_contig_4136_37	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.8	91	515	1197	4.43e-06	48.5
C137_contig_4136_47	SARG|gi|746243059|ref|WP_039291473.1|	28.9	211	515	648	1.42e-11	65.9
C137_contig_4136_47	SARG|gi|495736522|ref|WP_008461101.1|	29.9	211	515	648	1.88e-11	65.5
C137_contig_4136_47	SARG|gi|746253210|ref|WP_039301529.1|	29.9	211	515	648	2.48e-11	65.1
C137_contig_4136_47	SARG|gi|1001720867|ref|WP_061274204.1|	27.3	209	515	648	3.28e-11	64.7
C137_contig_4136_58	SARG|gi|445996729|ref|WP_000074584.1|	24.7	259	252	309	1.30e-16	76.6
C137_contig_4136_58	SARG|gi|445996709|ref|WP_000074564.1|	25.4	256	252	309	1.79e-16	76.3
C137_contig_4136_58	SARG|gi|446110087|ref|WP_000187942.1|	24.7	259	252	309	1.79e-16	76.3
C137_contig_4136_58	SARG|gi|445996714|ref|WP_000074569.1|	25.4	256	252	309	1.79e-16	76.3
C137_contig_4136_58	SARG|gi|814314593|emb|CKF49145.1|	25.4	256	252	309	1.79e-16	76.3
C137_contig_4136_58	SARG|gi|895736250|emb|COF64653.1|	25.0	256	252	309	3.36e-16	75.5
C137_contig_4136_58	SARG|gi|895808656|emb|COR83787.1|	25.0	256	252	309	3.36e-16	75.5
C137_contig_4136_58	SARG|gi|500194536|ref|WP_011867743.1|	27.5	200	252	306	4.47e-16	75.1
C137_contig_4136_58	SARG|gi|447195835|ref|WP_001273091.1|	28.0	200	252	306	4.47e-16	75.1
C137_contig_4136_58	SARG|gi|488068784|ref|WP_002140181.1|	24.8	254	252	309	4.60e-16	75.1
C137_contig_4122_13	SARG|gi|851935911|ref|WP_048224705.1|	34.5	275	307	660	7.48e-46	163
C137_contig_4122_13	SARG|gi|757799830|ref|WP_043017032.1|	34.9	275	307	660	7.48e-46	163
C137_contig_4122_13	SARG|gi|507079934|ref|WP_016150692.1|	34.5	275	307	660	1.03e-45	162
C137_contig_4122_13	SARG|gi|723045111|ref|WP_033545426.1|	35.3	275	307	660	1.42e-45	162
C137_contig_4122_13	SARG|ZP_04005119	35.3	275	307	660	1.42e-45	162
C137_contig_4122_13	SARG|gi|545232529|ref|WP_021532097.1|	35.3	275	307	660	1.96e-45	162
C137_contig_4122_13	SARG|Q8FFM1	35.3	275	307	660	1.96e-45	162
C137_contig_4122_13	SARG|A1ADA7	35.3	275	307	660	1.96e-45	162
C137_contig_4122_13	SARG|gi|545295454|ref|WP_021575742.1|	35.3	275	307	660	1.96e-45	162
C137_contig_4122_13	SARG|gi|1002399350|ref|WP_061382108.1|	34.2	275	307	660	1.96e-45	162
C137_contig_4122_16	SARG|CP001581.1.gene3143.p01	35.0	320	360	344	2.12e-58	191
C137_contig_4122_16	SARG|gb|CAL84423.1|ARO:3004146|cfrC	33.6	333	360	344	8.29e-58	190
C137_contig_4122_16	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	36.3	328	360	349	2.64e-57	189
C137_contig_4122_16	SARG|AJ249217.gene.p01	36.3	328	360	349	7.34e-57	187
C137_contig_4122_16	SARG|gb|BAD63613.1|ARO:3002816|clbC	34.7	334	360	350	1.15e-55	184
C137_contig_4122_18	CARD|gb|WKR28567.1|ARO:3007678|IreK	36.1	587	700	718	8.04e-86	284
C137_contig_4122_27	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.3	430	467	441	2.26e-35	135
C137_contig_4122_54	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	52.7	452	462	451	9.08e-145	420
C137_contig_4122_54	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	52.1	455	462	481	1.12e-142	416
C137_contig_4122_54	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	51.0	455	462	451	3.11e-140	409
C137_contig_4851_140	SARG|gb|CAE00499.1|ARO:3003835|cdeA	38.0	434	444	441	5.66e-97	297
C137_contig_4851_166	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	23.3	180	446	397	3.19e-07	51.2
